<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000066" GROUP_ID="PREG" ID="791499072713073822" MERGED_FROM="" MODIFIED="2012-10-05 10:42:35 +0100" MODIFIED_BY="Frances Kellie" NOTES="&lt;p&gt;Exported from Review Manager 4.2.5&lt;br&gt;Short title (no longer in use): Creams to prevent stretch marks in pregnancy&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2012-10-05 10:32:28 +0100" NOTES_MODIFIED_BY="Frances Kellie" REVIEW_NO="0013" REVMAN_SUB_VERSION="5.1.7" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.2">
<COVER_SHEET MODIFIED="2012-10-05 10:42:35 +0100" MODIFIED_BY="Frances Kellie">
<TITLE MODIFIED="2012-03-09 15:26:29 +0000" MODIFIED_BY="[Empty name]">Topical preparations for preventing stretch marks in pregnancy</TITLE>
<CONTACT MODIFIED="2012-10-05 10:42:35 +0100" MODIFIED_BY="Frances Kellie"><PERSON ID="16064" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gavin</FIRST_NAME><LAST_NAME>Young</LAST_NAME><EMAIL_1>gavinlyoung@btinternet.com</EMAIL_1><ADDRESS><ORGANISATION>Temple Sowerby Medical Practice</ORGANISATION><ADDRESS_1>Linden Park</ADDRESS_1><ADDRESS_2>Temple Sowerby</ADDRESS_2><CITY>Penrith</CITY><ZIP>CA10 1RW</ZIP><REGION>Cumbria</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 176 8361232</PHONE_1><FAX_1>+44 176 8361980</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-10-05 10:42:35 +0100" MODIFIED_BY="Frances Kellie"><PERSON ID="58724985989131097691110117130514" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Miriam</FIRST_NAME><LAST_NAME>Brennan</LAST_NAME><POSITION>Lecturer</POSITION><EMAIL_1>brennanm@nuigalway.ie</EMAIL_1><MOBILE_PHONE>087 2989756</MOBILE_PHONE><ADDRESS><DEPARTMENT>School of Nursing and Midwifery</DEPARTMENT><ORGANISATION>National University of Ireland Galway</ORGANISATION><CITY>Galway</CITY><COUNTRY CODE="IE">Ireland</COUNTRY><PHONE_1>+353 91 493651</PHONE_1><FAX_1>+353 91 494537</FAX_1></ADDRESS></PERSON><PERSON ID="16064" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gavin</FIRST_NAME><LAST_NAME>Young</LAST_NAME><EMAIL_1>gavinlyoung@btinternet.com</EMAIL_1><ADDRESS><ORGANISATION>Temple Sowerby Medical Practice</ORGANISATION><ADDRESS_1>Linden Park</ADDRESS_1><ADDRESS_2>Temple Sowerby</ADDRESS_2><CITY>Penrith</CITY><ZIP>CA10 1RW</ZIP><REGION>Cumbria</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 176 8361232</PHONE_1><FAX_1>+44 176 8361980</FAX_1></ADDRESS></PERSON><PERSON ID="15879" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Declan</FIRST_NAME><LAST_NAME>Devane</LAST_NAME><POSITION>Chair of Midwifery</POSITION><EMAIL_1>declan.devane@nuigalway.ie</EMAIL_1><ADDRESS><DEPARTMENT>School of Nursing and Midwifery</DEPARTMENT><ORGANISATION>National University of Ireland Galway</ORGANISATION><ADDRESS_1>University Road</ADDRESS_1><CITY>Galway</CITY><COUNTRY CODE="IE">Ireland</COUNTRY><PHONE_1>+353 91 495828</PHONE_1><FAX_1>+353 91 494537</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2012-03-15 09:29:29 +0000" MODIFIED_BY="Lynn Hampson">
<UP_TO_DATE>
<DATE DAY="6" MONTH="3" YEAR="2012"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="10" YEAR="2011"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="3" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1996"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="1996"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="1996"/>
</DATES>
<WHATS_NEW MODIFIED="2012-09-28 09:43:48 +0100" MODIFIED_BY="Lynn Hampson" NOTES="&lt;p&gt;Please update the date and information about the Update event in the description box as appropriate&lt;/p&gt;" NOTES_MODIFIED="2012-09-28 09:43:48 +0100" NOTES_MODIFIED_BY="Lynn Hampson">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2012-07-06 09:23:19 +0100" MODIFIED_BY="Lynn Hampson">
<DATE DAY="31" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>Two new authors helped prepare this updated review.</P>
<P>After restructuring the review's comparisons the review found no high-quality evidence to support the use of any of the topical preparations in the prevention of stretch marks during pregnancy.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2012-09-28 09:43:48 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="31" MONTH="10" YEAR="2011"/>
<DESCRIPTION>
<P>Two studies (three reports) identified in an earlier search have now been included in the review (<LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>).</P>
<P>An updated search identified a further six trials: two studies have been included (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>); two have been excluded (<LINK REF="STD-Mendez-Velarde-2010" TYPE="STUDY">Mendez Velarde 2010</LINK>; <LINK REF="STD-Msika-2002" TYPE="STUDY">Msika 2002</LINK>) and two are awaiting classification (<LINK REF="STD-Lachmann-2011" TYPE="STUDY">Lachmann 2011</LINK>; <LINK REF="STD-Ortega-1985" TYPE="STUDY">Ortega 1985</LINK>).</P>
<P>This review is now comprised of six included studies, four excluded studies and two studies that are awaiting classification.</P>
<P>The title has changed from 'Creams for preventing stretch marks in pregnancy' and the methods have been updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-12-13 15:24:13 +0000" MODIFIED_BY="Denise Atherton">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-04-29 15:17:52 +0100" MODIFIED_BY="Sonja L  Henderson">
<DATE DAY="1" MONTH="10" YEAR="2009"/>
<DESCRIPTION>
<P>Search updated. Three reports added to <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-10-26 12:05:01 +0000" MODIFIED_BY="Jill V Hampson">
<DATE DAY="1" MONTH="9" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-12-13 15:24:13 +0000" MODIFIED_BY="Denise Atherton">
<DATE DAY="30" MONTH="4" YEAR="2004"/>
<DESCRIPTION>
<P>Search updated. A second study (<LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>) has been reviewed. This compares massage using an ointment containing several possibly active ingredients with no treatment. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2012-10-05 10:31:22 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2012-09-28 09:55:26 +0100" MODIFIED_BY="Sonja L  Henderson">
<TITLE MODIFIED="2012-03-06 12:24:52 +0000" MODIFIED_BY="[Empty name]">Topical preparations for preventing stretch marks in pregnancy</TITLE>
<SUMMARY_BODY MODIFIED="2012-09-28 09:55:26 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>Stretch marks commonly develop during pregnancy, particularly in the third trimester. They affect 50% to 90% of women. They appear as red lines or streaks that fade slowly after the pregnancy to leave pale lines on the skin. The abdomen, breasts and thighs are most often affected. They do not disappear entirely, therefore any treatment which prevents them would be welcomed by many women. In this review, we identified randomised controlled trials and quasi-randomised controlled trials that compared topical creams, lotions and ointments containing active ingredients with placebo or no treatment, and topical preparations with active ingredients versus other topical preparations. </P>
<P>We included six trials (involving 800 women) in this review. We found that the application of a skin preparation to the areas affected by stretch marks during pregnancy did not prevent the development of stretch marks in the women during pregnancy. Only three trials (involving 461 women) looked at the severity of the stretch marks and did not show a clear difference. The preparations used included Alphastria, Trofolastin, Verum, olive oil and cocoa butter, which all contain vitamin E; Alphastria and Verum also have hyaluronic acid. Of the six trials, we judged three to be at low risk of bias. All trials were relatively small, with four of the six trials each including less than 100 women. The trials were also different in terms of when the women first started to use the topical applications, ranging from the first trimester to the first 20 weeks.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2012-09-28 09:45:47 +0100" MODIFIED_BY="Lynn Hampson">
<ABS_BACKGROUND MODIFIED="2012-09-19 03:28:14 +0100" MODIFIED_BY="[Empty name]">
<P>Striae gravidarum (stretch marks developing during pregnancy) occur in 50% to 90% of women. They appear as red or purple lines or streaks that fade slowly to leave pale lines or marks on the skin. The abdomen, breasts and thighs are commonly affected. The exact cause of stretch marks is unclear and no preparation has yet been shown to be effective in preventing the development of stretch marks. They are a source of significant anxiety for women, impacting on their quality of life.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-02-20 23:25:44 +0000" MODIFIED_BY="[Empty name]">
<P>To assess the effects of topical preparations on the prevention of stretch marks in pregnancy.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2012-09-24 12:11:51 +0100" MODIFIED_BY="Lynn Hampson">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 October 2011) and reference lists of retrieved reports.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2012-09-19 03:39:42 +0100" MODIFIED_BY="[Empty name]">
<P>We included randomised controlled trials and quasi-randomised controlled trials comparing topical preparations (with active ingredients) with other topical preparations (with active ingredients), with a placebo (that is, preparations without active ingredients) or with no treatment for the prevention of stretch marks in pregnant women.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2012-09-19 03:40:25 +0100" MODIFIED_BY="[Empty name]">
<P>Three review authors independently assessed trial eligibility and trial quality, and extracted data. Data were checked for accuracy. The primary outcome was the presence of stretch marks and the secondary outcome was the severity of stretch marks.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2012-09-28 09:45:47 +0100" MODIFIED_BY="Denise Atherton">
<P>We included six trials involving 800 women. Of the six trials, we judged the risk of bias for three as 'low risk' for random sequence generation, blinding of participants and personnel, blinding of outcome assessment, completeness of outcome data and selective reporting.</P>
<P>There was no statistically significant average difference in the development of stretch marks in women who received topical preparations with active ingredients compared to women who received a placebo or no treatment (average risk ratio (RR) 0.74; 95% confidence interval (CI) 0.53 to 1.03; five trials, 474 women; random-effects model, Tau² = 0.09, I² = 65%) (Analysis 1.1).</P>
<P>Results were consistent with the main effects when we performed a sensitivity analysis excluding studies judged to be at high risk of bias for random sequence generation, allocation concealment or more than 20% missing data for a given outcome (average RR 0.81; 95% CI 0.60 to 1.10; four trials, 424 women; random-effects model, Tau² = 0.05, I² = 57%).</P>
<P>The was no statistically significant average mean difference in the severity of stretch marks (standardised mean difference (SMD) -0.31; 95% CI -1.06 to 0.44; two trials, 255 women; Tau² = 0.26, I² = 87%).</P>
<P>There was no statistically significant difference in the development of stretch marks in women who received topical preparations with active ingredients compared to women who received other topical preparations with active ingredients (average RR 0.51; 95% CI 0.16 to 1.60; two trials, 305 women; Tau² = 0.53, I² = 74%). There was no statistically significant difference in the severity of stretch marks (mean difference (MD) -0.20; 95% CI -0.53 to 0.13; one trial, 206 women; heterogeneity not applicable).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2012-07-26 21:00:33 +0100" MODIFIED_BY="Denise Atherton">
<P>We found no high-quality evidence to support the use of any of the topical preparations in the prevention of stretch marks during pregnancy. There is a clear need for robust, methodologically rigorous randomised trials involving larger sample sizes to evaluate the effects of topical preparations on the development of stretch marks in pregnancy. In addition, it is important that preparations commonly used by women to prevent and treat stretch marks are evaluated within the context of robust, methodologically rigorous and adequately powered randomised trials.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2012-10-05 10:31:22 +0100" MODIFIED_BY="Gavin Young">
<BACKGROUND MODIFIED="2012-10-04 11:11:18 +0100" MODIFIED_BY="[Empty name]">
<P>The following review is an update of the review &#8216;Creams for preventing stretch marks in pregnancy&#8217; (<LINK REF="REF-Young-1996" TYPE="REFERENCE">Young 1996</LINK>).</P>
<CONDITION MODIFIED="2012-10-04 11:11:18 +0100" MODIFIED_BY="[Empty name]">
<P>Striae distensae (stretch marks), or striae gravidarum as they are known in pregnancy (<LINK REF="REF-Cunningham-2010" TYPE="REFERENCE">Cunningham 2010</LINK>), are considered to be the most common connective tissue change in pregnancy (<LINK REF="REF-Lawley-1999" TYPE="REFERENCE">Lawley 1999</LINK>). Rates of occurrence of striae gravidarum vary (<LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>), with reported rates ranging between 50% and 90% (<LINK REF="REF-Osman-2007" TYPE="REFERENCE">Osman 2007</LINK>). In primiparous women incidences of 52% (<LINK REF="REF-Atwal-2006" TYPE="REFERENCE">Atwal 2006</LINK>), 61% (<LINK REF="REF-Osman-2007" TYPE="REFERENCE">Osman 2007</LINK>) and 87.7% (<LINK REF="REF-Ghasemi-2007" TYPE="REFERENCE">Ghasemi 2007</LINK>) have been reported, while a rate of 71.1% was found in a study involving both primigravidae and multigravidae (<LINK REF="REF-Muzaffar-1998" TYPE="REFERENCE">Muzaffar 1998</LINK>). Striae gravidarum seem to affect all racial groups (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>). Although once considered to be more common in white than in black or Asian women (<LINK REF="REF-Wong-1984" TYPE="REFERENCE">Wong 1984</LINK>; <LINK REF="REF-Wong-1989" TYPE="REFERENCE">Wong 1989</LINK>), more recently non-white women were seen to be at greater risk (<LINK REF="REF-Chang-2004" TYPE="REFERENCE">Chang 2004</LINK>).<B> </B>Striae gravidarum are common during the first pregnancy (<LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>) and usually present during the third trimester (<LINK REF="REF-Atwal-2006" TYPE="REFERENCE">Atwal 2006</LINK>; <LINK REF="REF-Cunningham-2010" TYPE="REFERENCE">Cunningham 2010</LINK>). However, there have been reports in women under 24 weeks' gestation and of women first developing them in a second pregnancy (<LINK REF="REF-Chang-2004" TYPE="REFERENCE">Chang 2004</LINK>). </P>
<P>Striae have been defined as 'visible linear scars' (<LINK REF="REF-Burrows-2004" TYPE="REFERENCE">Burrows 2004</LINK>: 46.6) that have evolved through recognised stages (<LINK REF="REF-Kang-1996" TYPE="REFERENCE">Kang 1996</LINK>) similar to the stages of tissue healing (<LINK REF="REF-Kang-1998" TYPE="REFERENCE">Kang 1998</LINK>; <LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>) or scar formation (<LINK REF="REF-Elson-1990" TYPE="REFERENCE">Elson 1990</LINK>). They manifest as 'reddish slightly depressed streaks' (<LINK REF="REF-Cunningham-2010" TYPE="REFERENCE">Cunningham 2010</LINK>: 111) or 'reddish purple linear macules' (<LINK REF="REF-Horn-2007" TYPE="REFERENCE">Horn 2007</LINK>: 947). They often fade gradually (<LINK REF="REF-Kang-1996" TYPE="REFERENCE">Kang 1996</LINK>; <LINK REF="REF-Kang-1998" TYPE="REFERENCE">Kang 1998</LINK>; <LINK REF="REF-Papoutsis-2007" TYPE="REFERENCE">Papoutsis 2007</LINK>; <LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>) leaving glistening (<LINK REF="REF-Cunningham-2010" TYPE="REFERENCE">Cunningham 2010</LINK>), white depressed (<LINK REF="REF-Elson-1990" TYPE="REFERENCE">Elson 1990</LINK>) or pale wrinkled lines (<LINK REF="REF-Watson-1998" TYPE="REFERENCE">Watson 1998</LINK>) on the skin, from about six months following birth (<LINK REF="REF-Murray-2009" TYPE="REFERENCE">Murray 2009</LINK>). These glistening lines are commonly seen on multiparous women in addition to the reddish striae of the current pregnancy (<LINK REF="REF-Cunningham-2010" TYPE="REFERENCE">Cunningham 2010</LINK>). These benign skin changes (<LINK REF="REF-Atwal-2006" TYPE="REFERENCE">Atwal 2006</LINK>) commonly occur on the abdomen but are also seen on the breasts and thighs (<LINK REF="REF-Cunningham-2010" TYPE="REFERENCE">Cunningham 2010</LINK>; <LINK REF="REF-Horn-2007" TYPE="REFERENCE">Horn 2007</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>; <LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>; <LINK REF="REF-Thomas-2004" TYPE="REFERENCE">Thomas 2004</LINK>), hips and buttocks (<LINK REF="REF-Horn-2007" TYPE="REFERENCE">Horn 2007</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>) and groin and axillae (<LINK REF="REF-Papoutsis-2007" TYPE="REFERENCE">Papoutsis 2007</LINK>). Striae have been reported as ranging in severity and have been graded as mild, moderate or severe by some authors (<LINK REF="REF-Atwal-2006" TYPE="REFERENCE">Atwal 2006</LINK>; <LINK REF="REF-Osman-2007" TYPE="REFERENCE">Osman 2007</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>). <LINK REF="REF-Atwal-2006" TYPE="REFERENCE">Atwal 2006</LINK>: 966 developed and used a numerical system that captured the severity of striae, focusing on the number of striae present and the degree of erythema, or redness. A score of zero to three represented no striae or 'no significant striae', four to nine was considered 'mild', 10 to 15 as 'moderate' and greater than 16 represented 'severe striae'. Other criteria for assessing the severity of striae gravidarum include degrees of 'scaling, burning or stinging, or pruritus' (<LINK REF="REF-Kang-1996" TYPE="REFERENCE">Kang 1996</LINK>:520). </P>
<P>While attracting much discussion and debate over the years (<LINK REF="REF-Nigam-1989" TYPE="REFERENCE">Nigam 1989</LINK>), the exact cause or origin of striae gravidarum remains in doubt (<LINK REF="REF-Ghasemi-2007" TYPE="REFERENCE">Ghasemi 2007</LINK>; <LINK REF="REF-Lawley-1999" TYPE="REFERENCE">Lawley 1999</LINK>; <LINK REF="REF-Osman-2007" TYPE="REFERENCE">Osman 2007</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>; <LINK REF="REF-Wong-1984" TYPE="REFERENCE">Wong 1984</LINK>) and is understood poorly (<LINK REF="REF-Burrows-2010" TYPE="REFERENCE">Burrows 2010</LINK>), with researchers disagreeing about their histopathological origins (<LINK REF="REF-Zheng-1985" TYPE="REFERENCE">Zheng 1985</LINK>). Nevertheless, several risk factors have been identified. Early researchers attributed the development of striae to stretching (Wilks, 1861 cited by <LINK REF="REF-Poidevin-1959" TYPE="REFERENCE">Poidevin 1959</LINK>) and the stretch theory was accepted widely as the cause of striae gravidarum up until the middle of the last century (<LINK REF="REF-Poidevin-1959" TYPE="REFERENCE">Poidevin 1959</LINK>) when it became evident that other factors such as increased adrenal cortical activity may be involved (<LINK REF="REF-Poidevin-1959" TYPE="REFERENCE">Poidevin 1959</LINK>).  </P>
<P>From his study of 116 primigravid women, <LINK REF="REF-Poidevin-1959" TYPE="REFERENCE">Poidevin 1959</LINK> concluded that striae development was not solely reliant on stretching and that striae gravidarum should not be referred to as stretch marks. <LINK REF="REF-Poidevin-1959" TYPE="REFERENCE">Poidevin 1959</LINK> proposed the existence of a 'striae factor' for each woman and while not identifying what this 'striae factor' may be, he found a clear relationship between the reduced glucose tolerance in pregnancy, a sign of adrenocortical hyperactivity, and the development of striae. This link between increased adrenocortical hormonal activity and striae gravidarum has been suggested by others (<LINK REF="REF-Liu-1974" TYPE="REFERENCE">Liu 1974</LINK>; <LINK REF="REF-McKenzie-1971" TYPE="REFERENCE">McKenzie 1971</LINK>). <LINK REF="REF-Liu-1974" TYPE="REFERENCE">Liu 1974</LINK> asserts that striae gravidarum only develop in oestrogen and relaxin primed connective tissue, in response to stretching. Further, increased corticosteroid levels in pregnancy (<LINK REF="REF-Venning-1946" TYPE="REFERENCE">Venning 1946</LINK>) are thought to be a contributing factor. Oestrogen, relaxin and corticosteroids are thought to promote the formation of a type of mucopolysaccharide ground substance which promotes separation of the collagen fibrils (<LINK REF="REF-Bryant-1968" TYPE="REFERENCE">Bryant 1968</LINK>) and the formation of striae gravidarum in response to stretch (<LINK REF="REF-Liu-1974" TYPE="REFERENCE">Liu 1974</LINK>). Collagen is responsible for the tensile strength of the skin (<LINK REF="REF-Waugh-2010" TYPE="REFERENCE">Waugh 2010</LINK>) and under normal conditions the interfibrillar substance is highly viscous and there is no slipping or separation of collagen fibrils (<LINK REF="REF-Archer-2004" TYPE="REFERENCE">Archer 2004</LINK>). In pregnancy, the collagen mechanism is disrupted and irreversible sliding and separation of fibres occurs (<LINK REF="REF-Archer-2004" TYPE="REFERENCE">Archer 2004</LINK>). <LINK REF="REF-Liu-1974" TYPE="REFERENCE">Liu 1974</LINK>'s position on the development of striae gravidarum is challenged by <LINK REF="REF-Shuster-1979" TYPE="REFERENCE">Shuster 1979</LINK>, who contends that while the hormones of pregnancy may alter the collagen fibrils, there is no evidence to support this. Instead, <LINK REF="REF-Shuster-1979" TYPE="REFERENCE">Shuster 1979</LINK> suggests that striae are always due to stretching and, furthermore, only occur in immature connective tissue characterised by a "critical titre of rigid cross-linked collagen and elastic unlinked collagen" (<LINK REF="REF-Shuster-1979" TYPE="REFERENCE">Shuster 1979</LINK>: 161), which may be a factor in the higher risk of striae in younger women identified in some studies (<LINK REF="REF-Atwal-2006" TYPE="REFERENCE">Atwal 2006</LINK>; <LINK REF="REF-Murphy-1992" TYPE="REFERENCE">Murphy 1992</LINK>; <LINK REF="REF-Thomas-2004" TYPE="REFERENCE">Thomas 2004</LINK>). The stretching factor is supported by <LINK REF="REF-Thomas-2004" TYPE="REFERENCE">Thomas 2004</LINK> who suggest that the degree of stretch applied is also influential.  </P>
<P>Further insight into the pathogenesis of striae is given by <LINK REF="REF-Watson-1998" TYPE="REFERENCE">Watson 1998</LINK> who suggests that the development of striae is related to changes in the dermal elastic fibres rather than the collagen. They hypothesised that striae may occur in individuals where there is a deficiency in 'cutaneous fibrillin' and can arise in conditions like pregnancy where there is extra stretching on the skin. The extra strain or stretching could be sufficient to tear the elastic fibre network, resulting in the formation of striae (<LINK REF="REF-Watson-1998" TYPE="REFERENCE">Watson 1998</LINK>). Perhaps corticosteroids may also be influential here as they are thought to weaken the 'dermal elastic fibres' leading to their tearing (<LINK REF="REF-McKenzie-1971" TYPE="REFERENCE">McKenzie 1971</LINK>: 774).  However, it is far from conclusive, as <LINK REF="REF-Zheng-1985" TYPE="REFERENCE">Zheng 1985</LINK> suggest that striae are scars and are not due to rupture of the connective tissue in response to stress. They found that the elastic fibres and collagen arrangement were in keeping with a scar. Furthermore, they are characterised by absent rete ridges and a thinning and flattening of the overlying epidermis (<LINK REF="REF-Zheng-1985" TYPE="REFERENCE">Zheng 1985</LINK>) and are devoid of sweat glands or hair follicles.</P>
<P>While hormonal influences and stress or stretching factors continue to be considered important in the development of striae (<LINK REF="REF-Lawley-1999" TYPE="REFERENCE">Lawley 1999</LINK>), other risk factors have been associated with the development of striae gravidarum (<LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>). Identified risk factors include family history, race, skin type, birthweight, baseline body mass index, weight gain and inadequate nutrition (<LINK REF="REF-Osman-2007" TYPE="REFERENCE">Osman 2007</LINK>), younger maternal age, increased pregnancy weight gain, use of corticosteroids and a genetic susceptibility (<LINK REF="REF-Papoutsis-2007" TYPE="REFERENCE">Papoutsis 2007</LINK>). A number of researchers identified younger maternal age as a risk factor for the development of striae (<LINK REF="REF-Atwal-2006" TYPE="REFERENCE">Atwal 2006</LINK>; <LINK REF="REF-Murphy-1992" TYPE="REFERENCE">Murphy 1992</LINK>; <LINK REF="REF-Thomas-2004" TYPE="REFERENCE">Thomas 2004</LINK>) while others found no association with age (<LINK REF="REF-Ghasemi-2007" TYPE="REFERENCE">Ghasemi 2007</LINK>). Greater weight gain (<LINK REF="REF-Atwal-2006" TYPE="REFERENCE">Atwal 2006</LINK>; <LINK REF="REF-Murphy-1992" TYPE="REFERENCE">Murphy 1992</LINK>) and higher body mass (<LINK REF="REF-Thomas-2004" TYPE="REFERENCE">Thomas 2004</LINK>) have been identified as significant factors in the development of striae by some researchers while <LINK REF="REF-Chang-2004" TYPE="REFERENCE">Chang 2004</LINK> indicated that weight gain and changes in weight during pregnancy were less predictive of the development of striae than were genetic factors. A personal history of breast or thigh striae and genetic factors were thought to be the most predictive for the development of striae (<LINK REF="REF-Chang-2004" TYPE="REFERENCE">Chang 2004</LINK>). Family history was also identified by <LINK REF="REF-Osman-2007" TYPE="REFERENCE">Osman 2007</LINK>, where women with a family history of striae gravidarum were more likely to have moderate to severe striae gravidarum compared to those with no family history. Finally, a number of researchers have identified a significant relationship between the development of striae gravidarum and an increased infant birthweight (<LINK REF="REF-Atwal-2006" TYPE="REFERENCE">Atwal 2006</LINK>; <LINK REF="REF-Ghasemi-2007" TYPE="REFERENCE">Ghasemi 2007</LINK>; <LINK REF="REF-Murphy-1992" TYPE="REFERENCE">Murphy 1992</LINK>). </P>
<P>Striae have been a significant anxiety for women since early times (<LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>). They are an aesthetic concern for many women (<LINK REF="REF-Atwal-2006" TYPE="REFERENCE">Atwal 2006</LINK>; <LINK REF="REF-Chang-2004" TYPE="REFERENCE">Chang 2004</LINK>; <LINK REF="REF-Ghasemi-2007" TYPE="REFERENCE">Ghasemi 2007</LINK>; <LINK REF="REF-Osman-2007" TYPE="REFERENCE">Osman 2007</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>; <LINK REF="REF-Rangel-2001" TYPE="REFERENCE">Rangel 2001</LINK>) and can also be a source of stress (<LINK REF="REF-Chang-2004" TYPE="REFERENCE">Chang 2004</LINK>; <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>). They may also cause itching (<LINK REF="REF-Horn-2007" TYPE="REFERENCE">Horn 2007</LINK>; <LINK REF="REF-Lawley-1999" TYPE="REFERENCE">Lawley 1999</LINK>; <LINK REF="STD-Martius-1973" TYPE="STUDY">Martius 1973</LINK>; <LINK REF="REF-Muzaffar-1998" TYPE="REFERENCE">Muzaffar 1998</LINK>; <LINK REF="REF-Papoutsis-2007" TYPE="REFERENCE">Papoutsis 2007</LINK>; <LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>) or a burning sensation (<LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>) for some women. Authors differ in their evaluation of how symptomatic or not they are; some see them as often symptomatic (<LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>) while others report them as usually asymptomatic (<LINK REF="REF-Papoutsis-2007" TYPE="REFERENCE">Papoutsis 2007</LINK>). </P>
<SUBSECTION>
<HEADING LEVEL="2">Description of the intervention and how the intervention might work</HEADING>
<P>Many writers refer to the challenges of treating striae (<LINK REF="REF-Alster-1997" TYPE="REFERENCE">Alster 1997</LINK>; <LINK REF="REF-Elsaie-2009" TYPE="REFERENCE">Elsaie 2009</LINK>; <LINK REF="REF-Papoutsis-2007" TYPE="REFERENCE">Papoutsis 2007</LINK>), while their prevention has attracted somewhat less attention. Some argue that it may not be possible to prevent striae (<LINK REF="REF-Cunningham-2010" TYPE="REFERENCE">Cunningham 2010</LINK>). Yet, there are an abundance of products on the market claiming to prevent striae (<LINK REF="REF-Summers-2009" TYPE="REFERENCE">Summers 2009</LINK>).  Consequently, over the years women have used many approaches and preparations to either prevent or treat striae gravidarum, and often at great expense (<LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>). It appears that there are no specific treatments for striae (<LINK REF="REF-Elsaie-2009" TYPE="REFERENCE">Elsaie 2009</LINK>; <LINK REF="REF-Errickson-1994" TYPE="REFERENCE">Errickson 1994</LINK>; <LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>) and no preparation has yet been found to be effective in preventing or healing the lines that remain (<LINK REF="REF-Papoutsis-2007" TYPE="REFERENCE">Papoutsis 2007</LINK>). Approaches or preparations used in the prevention and treatment include topical preparations, lasers or pulsed light (<LINK REF="REF-Elsaie-2009" TYPE="REFERENCE">Elsaie 2009</LINK>). However, only topical preparations are considered safe to use in pregnancy and the theoretical reasoning for how they are thought to work include:</P>
<UL>
<LI>stimulation of fibroblastic activity leading to increased production of collagen and fibronectin (<LINK REF="REF-Brinkhaus-2000" TYPE="REFERENCE">Brinkhaus 2000</LINK>; <LINK REF="REF-Elsaie-2009" TYPE="REFERENCE">Elsaie 2009</LINK>);</LI>
<LI>increased blood perfusion through massaging of the area and potential anti-inflammatory effects (<LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>);</LI>
<LI>Increased skin hydration (<LINK REF="REF-Elsaie-2009" TYPE="REFERENCE">Elsaie 2009</LINK>). </LI>
</UL>
</SUBSECTION>
</CONDITION>
<IMPORTANCE MODIFIED="2012-09-19 05:17:28 +0100" MODIFIED_BY="[Empty name]">
<P>Striae gravidarum affect between 50% and 90% of women (<LINK REF="REF-Osman-2007" TYPE="REFERENCE">Osman 2007</LINK>) during pregnancy and usually remain as silvery scar lines on the skin. They are an unwanted consequence of pregnancy, impacting on women's perception of themselves (<LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>) and their quality of life (<LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>), and are thus of significant concern to women of child bearing age. </P>
<P>There are many unproven products on the market (<LINK REF="REF-Burrows-2010" TYPE="REFERENCE">Burrows 2010</LINK>) tried by many women. Consequently, many women incur great expense (<LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>) trying to prevent or treat striae (<LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>). It is important, therefore, to systematically assess the evidence on the effectiveness of these creams and preparations in the prevention of striae.  The findings of this review will benefit both women and healthcare professionals. The review will assist women to make informed decisions about their choice of treatment to prevent striae gravidarum and inform healthcare practitioners when advising women on the effectiveness of topical preparation for the prevention of striae gravidarum.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2011-07-10 12:31:23 +0100" MODIFIED_BY="[Empty name]">
<P>To assess the effects of topical preparations on the prevention of stretch marks in pregnancy.</P>
</OBJECTIVES>
<METHODS MODIFIED="2012-09-28 10:01:33 +0100" MODIFIED_BY="Gavin Young">
<SELECTION_CRITERIA MODIFIED="2012-09-19 05:23:19 +0100" MODIFIED_BY="Gavin Young">
<CRIT_STUDIES MODIFIED="2012-09-19 05:18:03 +0100" MODIFIED_BY="[Empty name]">
<P>All randomised and quasi-randomised controlled trials comparing topical preparations (with active ingredients) with other topical preparations (with active ingredients), with a placebo (that is, preparations without active ingredients) or with no treatment.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2012-09-19 05:18:59 +0100" MODIFIED_BY="[Empty name]">
<P>Pregnant women prior to 20 weeks' gestation, including women expecting their first or subsequent babies and women experiencing multiple pregnancies.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2012-09-19 05:23:10 +0100" MODIFIED_BY="Gavin Young">
<P>For the purpose of this review topical preparations are categorised as follows.</P>
<SUBSECTION>
<HEADING LEVEL="4">1.    Creams or lotions with active ingredients</HEADING>
<P>Creams and lotions are defined as emulsions with moisturising and emollient effects. They can be either be an 'oil-in-water' or a 'water-in-oil' emulsion (<LINK REF="REF-Hunter-1973" TYPE="REFERENCE">Hunter 1973</LINK>). Viscosity determines whether an emulsion is categorised as a lotion or a cream.</P>
<P>Examples include:</P>
<UL>
<LI>Trofolastin cream (containing Centella asiatica extract, alpha tocopherol and collagen-elastin hydrolysates) (<LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>);</LI>
<LI>Alphastria cream (containing hyaluronic acid, vitamins A and E, allantoin and calcium pantothenate) (<LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>);</LI>
<LI>cocoa butter lotion (containing cocoa butter and tocopheryl acetate (vitamin E) (<LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2.    Ointments with active ingredients</HEADING>
<P>Ointments are defined as semi-solid preparations and can be of three types: those that are 'water soluble', those that 'emulsify with water', or those that 'repel water' (<LINK REF="REF-Hunter-1973" TYPE="REFERENCE">Hunter 1973</LINK>: 412).</P>
<P>Examples include:</P>
<UL>
<LI>Verum ointment (containing vitamin E, essential free fatty acids, panthenol, hyaluronic acid, elastin and menthol) (<LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>).</LI>
</UL>
<P>For the purpose of this review, a placebo is a topical preparation without active ingredients, or 'no treatment'.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Comparisons</HEADING>
<OL>
<LI>Topical preparations with active ingredients compared with placebo or no treatment</LI>
<LI>Topical preparations with active ingredients compared with other topical preparations with active ingredients</LI>
</OL>
</SUBSECTION>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2012-09-19 05:23:19 +0100" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2012-09-19 05:23:18 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Presence of stretch marks</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2012-09-19 05:23:19 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Severity of stretch marks</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2012-09-24 12:14:39 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2012-09-24 12:14:39 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Pregnancy and Childbirth Group's Trials Register by contacting the Trials Search Co-ordinator (31 October 2011). The Trials Register is maintained by the Trials Search Co-ordinator and contains trials identified from: </P>
<OL>
<LI>quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL);</LI>
<LI>weekly searches of MEDLINE;</LI>
<LI>weekly searches of EMBASE;</LI>
<LI>handsearches of 30 journals and the proceedings of major conferences;</LI>
<LI>weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts.</LI>
</OL>
<P>Details of the search strategies for CENTRAL, MEDLINE and EMBASE, the list of handsearched journals and conference proceedings, and the list of journals reviewed via the current awareness service can be found in the &#8216;Specialized Register&#8217; section within the editorial information about the <A HREF="http://www.mrw.interscience.wiley.com/cochrane/clabout/articles/PREG/frame.html">Cochrane Pregnancy and Childbirth Group</A>. </P>
<P>Trials identified through the searching activities described above are each assigned to a review topic (or topics). The Trials Search Co-ordinator searches the register for each review using the topic list rather than keywords.  </P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2012-09-19 05:26:43 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the reference lists of all the identified studies and retrieved one trial (<LINK REF="STD-Msika-2002" TYPE="STUDY">Msika 2002</LINK>).</P>
<P>We did not apply any language restrictions.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2012-09-28 10:01:33 +0100" MODIFIED_BY="[Empty name]">
<P>For methods used in previous versions of this review, please see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>Methods for this update of the review are informed by the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<STUDY_SELECTION MODIFIED="2012-09-19 05:27:46 +0100" MODIFIED_BY="[Empty name]">
<P>Three review authors (M Brennan, D Devane, and G Young (MB, DD and GY) independently assessed all potential studies identified for inclusion as a result of the search strategy. We would have resolved any disagreements through discussion but this was not necessary.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2012-09-19 05:29:16 +0100" MODIFIED_BY="[Empty name]">
<P>We designed a form to extract data. For eligible studies, three review authors (MB, DD and GY) extracted the data using the agreed form. We resolved discrepancies through discussion. We contacted authors from two trials (Horace Fletcher for <LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; P Msika for Msika, unknown year) for further information (see notes in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>). All data were entered into the Review Manager software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) and checked for accuracy by the three review authors (MB, DD and GY).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2012-09-19 05:42:47 +0100" MODIFIED_BY="[Empty name]">
<P>Three review authors (MB, DD and GY) independently assessed the risk of bias for each study using criteria outlined in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). If there had been any discrepancies we would have resolved them through discussion, but this was not necessary.</P>
<SUBSECTION>
<HEADING LEVEL="4">(1) Random sequence generation (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to generate the allocation sequence in sufficient detail to allow an assessment of whether it should produce comparable groups.</P>
<P>We assessed the method as:</P>
<UL>
<LI> low risk (any truly random process, e.g. random number table; computer random number generator);</LI>
<LI> high risk (any non-random process, e.g. odd or even date of birth; hospital or clinic record number);</LI>
<LI> unclear risk (insufficient information to permit judgment).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4"> (2) Allocation concealment (checking for possible selection bias)</HEADING>
<P>We described for each included study the method used to conceal the allocation sequence and determined whether intervention allocation could have been foreseen in advance of or during recruitment, or changed after assignment.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes);</LI>
<LI>high risk (open random allocation; unsealed or non-opaque envelopes; alternation; date of birth);</LI>
<LI>unclear risk (insufficient information to permit judgment).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(3) Blinding of participants and personnel (checking for possible performance bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind study participants and personnel from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded or if we judged that the lack of blinding could not have affected the results.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk, high risk or unclear risk for participants;</LI>
<LI>low risk, high risk or unclear risk for personnel.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(4) Blinding of outcome assessment (checking for possible detection bias)</HEADING>
<P>We described for each included study the methods used, if any, to blind outcome assessors from knowledge of which intervention a participant received. We considered that studies were at low risk of bias if they were blinded, or if we judged that the lack of blinding could not have affected the results.</P>
<P>We assessed the methods as:· </P>
<UL>
<LI>low risk (no blinding of outcome assessment but the authors judged that the outcome was not likely to be influenced by this); </LI>
<LI>high risk (no blinding of outcome assessment and the outcome measurement was likely to have been influenced by this);</LI>
<LI>unclear risk (insufficient information to permit judgment; the study did not address this).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(5) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations)</HEADING>
<P>We described for each included study, and for each outcome or class of outcomes, the completeness of data including attrition and exclusions from the analysis. We stated whether attrition and exclusions were reported, the numbers included in the analysis at each stage (compared with the total number of randomised participants), reasons for attrition or exclusion where reported, and whether missing data were balanced across groups or were related to outcomes. Where sufficient information was reported, or was supplied by the trial authors, we re-included the missing data in the analyses we undertook.</P>
<P>We assessed the methods as:</P>
<UL>
<LI>low risk (20% or less of missing data);</LI>
<LI>high risk (more than 20% of missing data);</LI>
<LI>unclear risk (insufficient reporting to permit judgment; the study did not address this).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(6) Selective reporting (checking for reporting bias)</HEADING>
<P>We investigated the possibility of selective outcome reporting bias by identifying the outcomes in the study protocol (if available) and in the methods section of the publication, and by cross-checking to see if these outcomes were reported in the results section of the trial publication(s). PubMed and the World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) (<A HREF="http://www.who.int/ictrp/en/">http://www.who.int/ictrp/en/</A>) were searched for the study protocols.</P>
<P>We assessed the methods as:</P>
<UL>
<LI> low risk (where it was clear that all of the study&#8217;s pre-specified outcomes as identified in the study protocol (where available) and in the method's section were reported on; that all expected outcomes of interest to the review were reported on);</LI>
<LI>high risk (where it was clear that not all of the study's pre-specified outcomes as identified in the study protocol (where available) and in the method's section were reported on; failure to include a key outcome that would have been expected to have been included);</LI>
<LI>unclear risk (insufficient information to permit judgment).</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">(7) Other bias (checking for other biases)</HEADING>
<P>We described for each included study any important concerns we had about other possible sources of bias. We assessed whether each study was free of other problems that could put it at risk of bias as follows:</P>
<UL>
<LI>low risk (study appeared to be free of bias);</LI>
<LI>high risk (had at least one important risk of bias, for example related to study design);</LI>
<LI>unclear risk (insufficient information to permit judgment).</LI>
</UL>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2012-09-19 05:45:00 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>For dichotomous data, we presented the results as summary risk ratio (RR) with 95% confidence interval (CI).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>For continuous data, we used the mean difference for outcomes measured in the same way between trials. We used the standardised mean difference to combine trials that measured the same outcome but used different scales.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2012-09-19 05:47:38 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Cluster-randomised trials</HEADING>
<P>We did not identify any cluster-randomised trials in our search. In future updates of this review, if we identify any cluster-randomised trials we will include them along with individually randomised trials. We will adjust their sample sizes using the methods described in the <I>Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>) using an estimate of the intracluster correlation co-efficient (ICC) derived from the trial (if possible), from a similar trial, or from a study of a similar population. If we use ICCs from other sources we will report this and conduct sensitivity analyses to investigate the effect of variation in the ICC. If we identify cluster-randomised trials and individually-randomised trials we will synthesise the relevant information. We will consider it reasonable to combine the results from both where there is little heterogeneity between the study designs and where we consider that there is unlikely to be an interaction between the effect of the intervention and the choice of randomisation unit. We will acknowledge heterogeneity in the unit of randomisation and perform a sensitivity analysis to investigate the effects of this heterogeneity on the review findings.</P>
</SUBSECTION>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2012-09-19 05:50:45 +0100" MODIFIED_BY="[Empty name]">
<P>For included studies, we noted the levels of attrition.</P>
<P>For all outcomes we carried out analyses, as far as possible, on an intention-to-treat basis, that is we attempted to include all participants randomised to each group in the analyses, and all participants were analysed in the group to which they were allocated regardless of whether or not they received the allocated intervention. The denominator for each outcome in each trial was the number randomised minus any participants whose outcomes were known to be missing.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2012-09-28 09:45:47 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed statistical heterogeneity in each meta-analysis using the Tau² (tau-squared), I², and X² (Chi²) statistics. We regarded heterogeneity as substantial if:</P>
<P>(a) the I² value was high (exceeding 30%); and</P>
<P>either</P>
<P>(b) there was inconsistency between trials in direction or magnitude of effects (judged visually), or a low (&lt; 0.10) P value in the Chi² test for heterogeneity;</P>
<P>or</P>
<P>(c) the estimate of between-study heterogeneity ( Tau² ) was above zero.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2012-09-19 05:53:58 +0100" MODIFIED_BY="[Empty name]">
<P>As there were less than 10 studies included in the meta-analysis we did not investigate publication bias using funnel plots. In future updates of this review, if there are 10 or more studies included in the meta-analysis, we will assess funnel plot asymmetry visually and use formal tests for funnel plot asymmetry. For continuous outcomes, we will use the test proposed by <LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>, and for dichotomous outcomes we will use the test proposed by <LINK REF="REF-Harbord-2006" TYPE="REFERENCE">Harbord 2006</LINK>. If asymmetry is detected in any of these tests or is suggested by a visual assessment, we will performed exploratory analyses to investigate it.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2012-09-28 10:01:33 +0100" MODIFIED_BY="[Empty name]">
<P>We carried out statistical analysis using the Review Manager software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). As there was clinical diversity in respect of the interventions, that is each trial used a different topical preparation with different active ingredients, we used a random-effects model meta-analysis to produce an overall summary of the average treatment effect across the six included trials. This random-effects summary is treated as the average range of possible treatment effects and therefore the true effect differs in the different trials or varies '...across studies about an overall pooled value' (<LINK REF="REF-Riley-2011" TYPE="REFERENCE">Riley 2011</LINK>). For each outcome reported, we presented the results of the random-effects model analyses as the average treatment effect with its 95% confidence interval, and the estimates of Tau² and I².</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2012-09-19 06:00:37 +0100" MODIFIED_BY="[Empty name]">
<P>We neither planned nor conducted any subgroup analyses.</P>
<P>In future updates of this review, if we identify substantial heterogeneity we will investigate it using subgroup analyses and sensitivity analyses. We will consider whether an overall summary is meaningful and, if it is, use random-effects model analysis to produce it.</P>
<P>We plan to carry out the following subgroup analysis.</P>
<OL>
<LI>Parity (nulliparous versus multiparous women).</LI>
</OL>
<P>Subgroup analysis will be restricted to primary outcomes.</P>
<P>We will assess subgroup differences by the interaction tests available within RevMan (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>). We will report the results of subgroup analyses quoting the &#967;<SUP>2</SUP> statistic and P value, and the interaction statistic I² value.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2012-09-19 06:03:04 +0100" MODIFIED_BY="[Empty name]">
<P>The previous version of this review (<LINK REF="REF-Young-1996" TYPE="REFERENCE">Young 1996</LINK>) did not include any a priori sensitivity analysis. In this update we undertook a sensitivity analysis by trial quality, by removing from the analysis those studies judged to be at high risk of bias for random sequence generation, allocation concealment, or with more than 20% missing data for a given outcome. In future updates of this review, the criteria for sensitivity analysis will broaden to determine the effect of also excluding trials judged to be at high risk of bias for blinding.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2012-10-05 10:31:20 +0100" MODIFIED_BY="Gavin Young">
<STUDY_DESCRIPTION MODIFIED="2012-09-19 06:15:13 +0100" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2012-09-19 06:07:02 +0100" MODIFIED_BY="[Empty name]">
<P>Our updated search identified a total of 13 reports relating to 12 trials (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>; <LINK REF="STD-Lachmann-2011" TYPE="STUDY">Lachmann 2011</LINK>; <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Martius-1973" TYPE="STUDY">Martius 1973</LINK>; <LINK REF="STD-Mendez-Velarde-2010" TYPE="STUDY">Mendez Velarde 2010</LINK>; <LINK REF="STD-Msika-2002" TYPE="STUDY">Msika 2002</LINK>; <LINK REF="STD-Ortega-1985" TYPE="STUDY">Ortega 1985</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>; <LINK REF="STD-Puder--1965" TYPE="STUDY">Puder 1965</LINK>; <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>; <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>). Eight new potential trials for inclusion were identified (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>; <LINK REF="STD-Lachmann-2011" TYPE="STUDY">Lachmann 2011</LINK>; <LINK REF="STD-Mendez-Velarde-2010" TYPE="STUDY">Mendez Velarde 2010</LINK>; <LINK REF="STD-Msika-2002" TYPE="STUDY">Msika 2002</LINK>; <LINK REF="STD-Ortega-1985" TYPE="STUDY">Ortega 1985</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>; <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>) in addition to the four studies (<LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Martius-1973" TYPE="STUDY">Martius 1973</LINK>; <LINK REF="STD-Puder--1965" TYPE="STUDY">Puder 1965</LINK>; <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>) included in the previous version of this review (<LINK REF="REF-Young-1996" TYPE="REFERENCE">Young 1996</LINK>). All of the trials were retrieved via the search of the Cochrane Pregnancy and Childbirth Group Trials Register with the exception of two studies (<LINK REF="STD-Lachmann-2011" TYPE="STUDY">Lachmann 2011</LINK>; <LINK REF="STD-Msika-2002" TYPE="STUDY">Msika 2002</LINK>). <LINK REF="STD-Msika-2002" TYPE="STUDY">Msika 2002</LINK> was found from searching reference lists of retrieved studies and <LINK REF="STD-Lachmann-2011" TYPE="STUDY">Lachmann 2011</LINK> via communication with Expanscience Laboratories in France during our attempts to get more information on <LINK REF="STD-Msika-2002" TYPE="STUDY">Msika 2002</LINK>. Other searches did not yield any further potentially eligible studies.</P>
<P>This updated review includes six studies (involving 800 women). Two additional trials (<LINK REF="STD-Lachmann-2011" TYPE="STUDY">Lachmann 2011</LINK>; <LINK REF="STD-Ortega-1985" TYPE="STUDY">Ortega 1985</LINK>) are awaiting classification. Despite translating the paper, there was insufficient information on the randomisation process to judge if the study by <LINK REF="STD-Ortega-1985" TYPE="STUDY">Ortega 1985</LINK> was eligible for inclusion and attempts to contact the authors have been unsuccessful (see <LINK TAG="AWAITING_STUDIES" TYPE="SECTION">Studies awaiting classification</LINK>). We are awaiting the translated report of <LINK REF="STD-Lachmann-2011" TYPE="STUDY">Lachmann 2011</LINK> from Expanscience Laboratories (France).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2012-09-19 06:13:50 +0100" MODIFIED_BY="[Empty name]">
<P>This update includes four (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>; <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>) new studies bringing the total number of included studies to six (involving a total of 800 women) (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>; <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>; <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>; <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>) (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
<P>Included studies were undertaken in Germany (<LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>), Spain (<LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>), Austria (<LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>), West Indies (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>), Lebanon (<LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>) and Iran (<LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>) and were conducted mainly in antenatal clinics and medical centres.</P>
<P>Two studies compared topical preparations with active ingredients with placebo, that is Trofolastin (which contains Centella asiatica extract, alpha tocopherol and collagen-elastin hydrolysates) versus placebo cream (<LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>) and cocoa butter lotion versus placebo lotion (<LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>). Two studies compared topical preparations with active ingredients with no treatment, that is olive oil versus no treatment (<LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>) and Verum ointment (which contains vitamin E, essential free fatty acids (vitamin F), panthenol, hyaluronic acid, elastin and menthol) versus no treatment (<LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>). One study compared topical preparations with active ingredients with other topical preparations with active ingredients, that is cocoa butter cream versus a similar cream with vitamin E and other constituents but without cocoa butter (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>). Finally, one study included two intervention groups and a placebo group; topical preparations with active ingredients were compared with other topical preparations with active ingredients, and topical preparations with active ingredients were compared with placebo, that is Alphastria cream (which contains hyaluronic acid, vitamin A, vitamin E, allantoine, calcium pantothenate) versus a cream with vitamins and excipients, and Alphastria cream and cream with vitamins and excipients versus a cream with excipients only (<LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2012-09-19 06:15:13 +0100" MODIFIED_BY="[Empty name]">
<P>For this update, we have added two new excluded studies (<LINK REF="STD-Mendez-Velarde-2010" TYPE="STUDY">Mendez Velarde 2010</LINK>; <LINK REF="STD-Msika-2002" TYPE="STUDY">Msika 2002</LINK>) bringing the total number of excluded studies to four (<LINK REF="STD-Martius-1973" TYPE="STUDY">Martius 1973</LINK>; <LINK REF="STD-Mendez-Velarde-2010" TYPE="STUDY">Mendez Velarde 2010</LINK>; <LINK REF="STD-Msika-2002" TYPE="STUDY">Msika 2002</LINK>; <LINK REF="STD-Puder--1965" TYPE="STUDY">Puder 1965</LINK>) (see <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2012-09-19 06:24:12 +0100" MODIFIED_BY="Gavin Young">
<P>We assessed the risk of bias in the included studies (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Overall, the studies were at low or unclear risk of bias across most domains (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). No study was at low risk of bias across all seven domains, while three studies (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>) were at low risk of bias across five of the seven domains and one study (<LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>) was at low risk of bias across four of the seven domains. All of the included studies were at unclear risk of bias for allocation concealment except for <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>, which was at high risk of bias (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>). Details of risk of bias within domains and across studies are given below.</P>
<ALLOCATION MODIFIED="2012-09-19 06:18:15 +0100" MODIFIED_BY="[Empty name]">
<P>Four of the six included studies (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>; <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>) were at low risk of bias in random sequence generation, one was at unclear risk (<LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>) and one was at high risk (<LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>). <LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK> was at unclear risk due to insufficient information to judge the risk of bias, while <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK> was at high risk of bias as alternate day allocation was used to enrol women in the treatment groups. On uneven dates women were included in the treatment group and on even dates women were enrolled in the no treatment group.</P>
<P>Five of the six included studies (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>; <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>; <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>) were at unclear risk of bias in allocation concealment and <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK> was at high risk of bias. Two of the six studies, with unclear risk of bias for allocation concealment (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>), had insufficient information to judge the risk of bias while three of the other four (<LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>; <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>) reported insufficient information on how women were allocated to the study groups. In <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK> randomisation was performed according to day of treatment (that is, alternate days).</P>
</ALLOCATION>
<BLINDING MODIFIED="2012-09-19 06:19:06 +0100" MODIFIED_BY="[Empty name]">
<P>Three of the six included studies (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>) were at low risk of bias in blinding of participants and personnel and in blinding of outcome assessment. Three of the six included studies were at unclear risk (<LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>; <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>; <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>) due to insufficient or no information reported to permit judgement of risk of bias for performance or detection bias.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2012-09-19 06:21:01 +0100" MODIFIED_BY="[Empty name]">
<P>Five of the six included studies (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>; <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>; <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>) were at low risk of bias for incomplete outcome data and one study was at unclear risk (<LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>). In the study by <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK> the number of women randomised was not given, only the number of women included in the analysis. In the <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK> trial report it was not stated explicitly how many women were randomised, but it was stated that &#8216;The assay was carried out on 100 pregnant women&#8217;. They reported total &#8216;valid&#8217; cases as 41 for intervention (active cream) and 39 for placebo. Assuming 100 women were randomised, then 20 women were excluded from the analysis overall, giving 20% incomplete outcome data (low risk) (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>).</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2012-09-19 06:21:13 +0100" MODIFIED_BY="Gavin Young">
<P>All of the six included studies (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>; <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>; <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>; <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>) were at low risk of bias in selective reporting.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2012-09-19 06:24:12 +0100" MODIFIED_BY="[Empty name]">
<P>We judged two of the six included studies (<LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>; <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>) to be at low risk of other biases, and four studies (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>; <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>) at unclear risk of other biases. In the studies by <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK> and <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>, the number of women randomised to each group were not stated explicitly, while in the studies by <LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; and <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK> the researchers raised concerns regarding intervention fidelity. <LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>: 68 stated '...that it was not possible to verify that the patients were using the cream as instructed or whether they were sharing the cream or using other creams', while <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>: 1142 stated that 'Reports of compliance varied greatly for each patient and assessors reported that women may have been telling them what they wanted to hear when they asked about compliance'. They acknowledged that compliance may have been an issue in the study but that use of the study lotion reflected general population use (<LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>: 1142). Therefore, we judged <LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK> and <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK> to be at unclear risk of other biases.</P>
<P>The source of funding was not identified for all but two of the included studies, <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK> where both intervention and placebo lotions were provided by ET Browne Drug Company, Inc and <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK> where the authors declared no funding source.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2012-10-05 10:31:20 +0100" MODIFIED_BY="[Empty name]">
<P>This updated review now includes data from six studies involving 800 women.</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Topical preparations with active ingredients compared with placebo or no treatment (five trials and 474 women)</HEADING>
<P>This comparison includes data from the following studies: <LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>; <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>; <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>; <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome (five trials and 474 women)</HEADING>
<P>There was no statistically significant average difference in the development of stretch marks in women who received topical preparations with active ingredients compared to women who received a placebo or no treatment (average risk ratio (RR) 0.74; 95% confidence interval (CI) 0.53 to 1.03; five trials, 474 women; random-effects model, Tau² = 0.09, I² = 65%) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>).</P>
<P>Results were consistent with the main effects when we performed a sensitivity analysis, excluding the <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK> study which was at high risk of bias for random sequence generation and allocation concealment (average RR 0.81; 95% CI 0.60 to 1.10; four trials, 424 women; random-effects model, Tau² = 0.05, I² = 57%).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome (two trials and 255 women)</HEADING>
<P>There was no statistically significant average mean difference in the severity of stretch marks in women who received topical preparations with active ingredients compared to women who received a placebo or no treatment (standardised mean difference (SMD) -0.31; 95% CI -1.06 to 0.44; two trials, 255 women; random-effects model, Tau² = 0.26, I² = 87%) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). The heterogeneity between the two trials was large and therefore the average result may not be meaningful, that is it is unlikely that such an average effect would be found in real life (the effect could be similar to one or other of the trials, but unlikely to be an 'average' of both).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Topical preparations with active ingredients compared with other topical preparations with active ingredients (two trials and 305 women)</HEADING>
<P>This comparison included two studies with 305 women (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>). <LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK> compared cocoa butter cream, which contained a variety of constituents for example 25% cocoa butter, glycerin, isopropyl palmitate, hydrolysed collagen, hydrolysed elastin and tocopheryl acetate (vitamin E) with a cream identical to the intervention cream but without the 25% cocoa butter. In the second trial (<LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>), Alphastria cream (containing hyaluronic acid, vitamin A, vitamin E, allantoine, calcium pantothenate) was compared with a cream with vitamins and excipients.</P>
<SUBSECTION>
<HEADING LEVEL="4">Primary outcome</HEADING>
<P>There was no statistically significant average difference in the development of stretch marks in women who received topical preparations with active ingredients compared to women who received other topical<B> </B>preparations with active ingredients (average RR 0.51; 95% CI 0.16 to 1.60; two trials, 305 women; random-effects model, Tau² = 0.53, I² = 74%) (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Secondary outcome (one trial and 206 women)</HEADING>
<P>The was no statistically significant mean difference in the severity of stretch marks in women who received topical preparations with active ingredients compared to women who received other topical preparations with active ingredients (mean difference (MD) -0.20; 95% CI -0.53 to 0.13; one trial, 206 women; heterogeneity not applicable) (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2012-10-05 10:31:22 +0100" MODIFIED_BY="Gavin Young">
<P>Stretch marks are a very common connective tissue change that can occur in pregnancy (<LINK REF="REF-Lawley-1999" TYPE="REFERENCE">Lawley 1999</LINK>), affecting between 50% and 90% (<LINK REF="REF-Osman-2007" TYPE="REFERENCE">Osman 2007</LINK>) of women and remaining as silvery scar lines on the skin. They are an unwanted consequence of pregnancy, impacting on women's perception of themselves (<LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>) and their quality of life (<LINK REF="REF-Salter-2006" TYPE="REFERENCE">Salter 2006</LINK>), and are thus of significant concern to women of child bearing age. There are many products of unproven effectiveness on the market (<LINK REF="REF-Burrows-2010" TYPE="REFERENCE">Burrows 2010</LINK>), which are tried by many women. This review assessed the effects of topical preparations on the prevention of stretch marks in pregnancy.</P>
<P>The review includes six trials (involving a total of 800 women) conducted mainly in antenatal clinics and medical centres in varied geographical locations. It should be noted that the random-effects model summaries presented are the average effects found for both the development and severity of stretch marks. The use of the random-effects model is based on the assumption that the treatment effect will be different across the studies due to heterogeneity between the studies. It therefore calculates the average of all the treatment effects across the trials (<LINK REF="REF-Riley-2011" TYPE="REFERENCE">Riley 2011</LINK>) and thus may not be the actual effect in any of the included studies.</P>
<SUMMARY_OF_RESULTS MODIFIED="2012-10-05 10:31:22 +0100" MODIFIED_BY="Gavin Young">
<SUBSECTION>
<HEADING LEVEL="3">Topical preparations with active ingredients compared with placebo or no treatment</HEADING>
<P>This review found that there was no statistically significant average difference in the development of stretch marks in women who received topical preparations with active ingredients compared to women who received a placebo or no treatment. All studies were relatively small, with four of the five trials including less than 100 women (<LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>; <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>; <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>) and one trial by <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK> including less than 200 women as reflected in the narrower confidence interval.</P>
<P>Trials differed in relation to the timing of commencement of the topical applications. Three of the five studies included women presenting in trimester one (<LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>; <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>) while <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK> and <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK> recruited women at 18 to 20 weeks and 20 weeks' gestation, respectively. All trials recruited women prior to the third trimester when stretch marks usually occur (<LINK REF="REF-Atwal-2006" TYPE="REFERENCE">Atwal 2006</LINK>; <LINK REF="REF-Cunningham-2010" TYPE="REFERENCE">Cunningham 2010</LINK>).</P>
<P>Parity of the women participating in the included trials also differed. <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK> included both multigravidae and primigravidae, while <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK> and <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK> included primigravidae women only in their studies. The study by <LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK> identifies that one case of stretch marks occurred in a twin pregnancy in the intervention group receiving with active ingredients (Group A). No information on parity was given for the other included study (<LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>). It is likely, therefore, that some of the women in some trials had stretch marks from an earlier pregnancy, while the inclusion of some women with a multiple pregnancy may have increased the likelihood of those women developing stretch marks. In a multiple pregnancy there may be extra strain and, as suggested by <LINK REF="REF-Watson-1998" TYPE="REFERENCE">Watson 1998</LINK>, extra strain or stretching could be sufficient to tear the elastic fibre network, resulting in the formation of striae.</P>
<P>While topical preparations varied, many of them included some common ingredients. For example, two trials (<LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>; <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>) included hyaluronic acid in the active topical preparation (that is Alphastria cream and Verum ointment, respectively). Hyaluronic acid has been identified as stimulating fibroblastic activity (<LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>), and fibroblasts are key cells in maintaining tissue structure and tone. A number of the preparations also contained vitamin E (<LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>; <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>; <LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>; <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>), which promotes the development of the intracellular substance (<LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>) and is a known antioxidant used in many skin products. However, it is not evident which, if any, of these ingredients could exert a possible preventative action for the formation of striae.</P>
<P>We found no<B> </B>statistically significant average difference in the severity of stretch marks in women who received topical preparations with active ingredients compared to women who received a placebo or no treatment. Data on the severity of stretch marks were only available in two of the five included studies (<LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>). In the study by <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>, severity was assessed by trained assessors using a validated tool, while <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK> refers to using 'an arbitrary score 0 = no striae, 1 = few and thin striae, 2 = many thin striae or few thick striae, and 3 = many thick striae'. Neither study refers to inter-rater reliability and therefore it is unclear how errors in measurement were minimised.</P>
<P>From a clinical perspective while none of the topical products in the included trials (Alphastria cream, Trofolastin, cocoa butter lotion, olive oil, and Verum), with the exception of cocoa butter lotion (<LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>) and olive oil (<LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>), appear to be widely available, some women may indeed be applying cocoa butter lotion or olive oil in the hope of preventing the development of stretch marks. However, this review found no statistically significant average difference in the development of stretch marks in women who received topical preparations with active ingredients compared to women who received a placebo or no treatment. Therefore, based on this review it is not possible to recommend any of the preparations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Topical preparations with active ingredients compared with other topical preparations with active ingredients</HEADING>
<P>This review found no<B> </B>statistically significant average difference in the development of stretch marks or in the severity of stretch marks in women who received topical preparations with active ingredients compared with other topical preparations with active ingredients in trials (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>) involving small numbers of participants. In the trial by <LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>, the topical preparations contained multiple ingredients including isopropyl palmitate (emollient), propylene glycol isostearate (emollient), PPG-15 stearyl ether (1-octadecoxypropan-2-ol) (emollient), hydrolysed collagen, hydrolysed elastin and tocopheryl acetate (vitamin E). Preparations differed only in the addition of cocoa butter (25%). In the study by <LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>, the intervention preparation contained several ingredients (hyaluronic acid, vitamin A, vitamin E, allantoine, calcium pantothenate) while the comparison preparation contained vitamins in addition to the excipient.</P>
<P>Data on the severity of stretch marks were only available in one of the two included studies (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>). In this study, <LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK> assessed the severity of stretch marks using the '4 quadrant technique of Davey (1972) with a simplification by Fletcher (unpublished)'. The researchers outline the process of ensuring that assessments were reliable and state that checking of researchers' assessments was undertaken with the aid of digital photographs until such time as 'a consensus of the striae scoring system by different observers' was achieved.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2012-09-19 06:44:37 +0100" MODIFIED_BY="[Empty name]">
<P>Based on the findings of this review, which included six small trials, it is not possible to recommend any of the preparations for the prevention of stretch marks in pregnancy .</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2012-09-19 06:46:15 +0100" MODIFIED_BY="[Empty name]">
<P>We assessed the risk of bias of included trials as 'low risk' for random sequence generation, blinding of participants and personnel, and in blinding of outcome assessment, complete outcome data and selective reporting in only three of the six trials (<LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>; <LINK REF="STD-Osman-2008" TYPE="STUDY">Osman 2008</LINK>). We assessed one study (<LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>) as at high risk of bias for random sequence generation and allocation concealment. Overall findings are not sensitive to exclusion of this study.</P>
<P>The quality of evidence is also impacted on by the possible imprecision of the study results due to the small numbers of participants and events, and their wide confidence intervals. This is particularly evident in some of the trials (<LINK REF="STD-Taavoni-2011" TYPE="STUDY">Taavoni 2011</LINK>; <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2012-09-24 12:20:48 +0100" MODIFIED_BY="[Empty name]">
<P>We have taken every step to ensure that there are no potential biases in the review processes. We undertook a systematic and comprehensive search without language restrictions and adhered to best practice in undertaking the review. Three authors (MB, DD and GY) independently assessed each study and agreed the studies that were for inclusion in the review and those that were for exclusion. Data extraction was also completed independently and checked for accuracy by three authors (MB, DD and GY). We contacted authors from two trials (Horace Fletcher for <LINK REF="STD-Buchanan--2010" TYPE="STUDY">Buchanan 2010</LINK>; P Msika for <LINK REF="STD-Msika-2002" TYPE="STUDY">Msika 2002</LINK>) for further information (see notes in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>). All data were entered into the Review Manager software (<LINK REF="REF-RevMan-2011" TYPE="REFERENCE">RevMan 2011</LINK>) and checked for accuracy by three authors (MB, DD and GG). Consequently, biases in the review processes are unlikely.</P>
</POTENTIAL_BIASES>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2012-09-19 06:49:20 +0100" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2012-06-14 13:03:14 +0100" MODIFIED_BY="[Empty name]">
<P>We found no high-quality evidence to support the use of any of the topical preparations in the prevention of stretch marks during pregnancy. </P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2012-09-19 06:49:20 +0100" MODIFIED_BY="[Empty name]">
<P>There is a clear need for robust, methodologically rigorous randomised trials involving larger sample sizes to evaluate the effects of topical preparations on the development of stretch marks in pregnancy.</P>
<P>Preparations possibly worth pursuing might include Trofolastin (<LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>), Alphastria (<LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>), and Verum (<LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK>). The latter two preparations contain hyaluronic acid, which has been identified as stimulating fibroblastic activity (<LINK REF="STD-de-Buman-1987" TYPE="STUDY">de Buman 1987</LINK>) and therefore maintaining tissue structure and tone. In addition, it is important that preparations commonly used by women to prevent and treat stretch marks are evaluated within the context of robust, methodologically rigorous and adequately powered randomised trials.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2012-09-07 10:30:45 +0100" MODIFIED_BY="[Empty name]">
<P>We would like to acknowledge the assistance of Luciana Figuera, Charlese Allen, Caroline Summers and Gloria Avalos who kindly did some translations of non-English language papers for us.</P>
<P>We thank David Jewell for his contribution to the original version of this review.</P>
<P>As part of the pre-publication editorial process, this review has been commented on by four peers (an editor and three referees who are external to the editorial team), a member of the Pregnancy and Childbirth Group's international panel of consumers and the Group's Statistical Adviser.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2012-09-24 12:17:03 +0100" MODIFIED_BY="[Empty name]">
<P>None known.<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2012-03-22 12:30:43 +0000" MODIFIED_BY="[Empty name]">
<P>All review authors (MB, GY and DD) prepared this review update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2012-09-19 06:51:50 +0100" MODIFIED_BY="Sonja L  Henderson">
<P>We have separated outcomes into primary and secondary outcomes. The outcome from the previous version of this review (presence of stretch marks) is our primary outcome and we have added a new secondary outcome (severity of stretch marks). The methods have been updated to reflect the latest <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
<P>We have also changed the title of the review from 'Creams for preventing stretch marks in pregnancy' to 'Topical preparations for preventing stretch marks in pregnancy'.</P>
<P>For this update we restructured the review comparisons to compare: (1) topical preparations with active ingredients compared with placebo or no treatment, and (2) topical preparations with active ingredients compared with other topical preparations with active ingredients. This is in contrast to comparing active creams with placebo or with no treatment, as presented in <LINK REF="REF-Young-1996" TYPE="REFERENCE">Young 1996</LINK>.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2012-09-19 06:53:08 +0100" MODIFIED_BY="[Empty name]">
<P>In the next update of this review we will carry out subgroup analysis by parity (nulliparous versus multiparous women), and our criteria for sensitivity analysis will incorporate trials at high risk of bias for blinding. We will also detail how the primary (presence of stretch marks) and secondary (severity of stretch marks) outcomes are measured and by whom. We will include a discussion around if and how included studies have addressed confounding or other risk factors.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2012-09-24 12:18:50 +0100" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2012-09-19 07:06:22 +0100" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2012-06-25 21:40:17 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Buchanan--2010" MODIFIED="2011-10-05 14:19:26 +0100" MODIFIED_BY="[Empty name]" NAME="Buchanan  2010" YEAR="2010">
<REFERENCE MODIFIED="2011-10-05 14:19:26 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buchanan K, Fletcher HM, Reid M</AU>
<TI>Prevention of striae gravidarum with cocoa butter cream</TI>
<SO>International Journal of Gynecology and Obstetrics</SO>
<YR>2010</YR>
<VL>108</VL>
<NO>1</NO>
<PG>65-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-07-18 10:56:37 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Buman-1987" MODIFIED="2010-12-13 12:41:55 +0000" MODIFIED_BY="Lynn Hampson" NAME="de Buman 1987" YEAR="1987">
<REFERENCE MODIFIED="2010-12-13 12:41:55 +0000" MODIFIED_BY="Lynn Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Buman M, Walther M, de Weck R</AU>
<TI>Effectiveness of Alphastria cream in the prevention of pregnancy stretch marks (striae distensae). Results of a double-blind study</TI>
<TO>Wirksamkeit der Alphastria-Creme bei der Vorbeugung von Schwangerschaftsstreifen (Striae distensae). Ergebnisse einer Doppelblind-Studie</TO>
<SO>Gynakologische Rundschau</SO>
<YR>1987</YR>
<VL>27</VL>
<PG>79-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2010-12-13 12:36:54 +0000" MODIFIED_BY="Lynn Hampson"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mallol-1991" MODIFIED="2012-06-25 21:40:17 +0100" MODIFIED_BY="[Empty name]" NAME="Mallol 1991" YEAR="1991">
<REFERENCE MODIFIED="2012-06-25 21:40:17 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Belda MA, Costa D, Noval A, Sola M, Mallol J. Prophylaxis of striae gravidarum with a topical formulation - a double blind study . Proceedings of 22nd International Congress of Confederation of Midwives; 1991 October 7-12; Kobe, Japan, 1991&lt;/p&gt;" NOTES_MODIFIED="2012-06-25 21:40:17 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Belda MA, Costa D, Noval A, Sola M, Mallol J</AU>
<TI>Prophylaxis of striae gravidarum with a topical formulation - a double blind study</TI>
<SO>Proceedings of 22nd International Congress of Confederation of Midwives; 1990 October 7-12; Kobe, Japan</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;[6452]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mallol J, Belda MA, Costa D, Noval A, Sola M</AU>
<TI>Prophylaxis of striae gravidarum with a topical formulation. A double blind trial</TI>
<SO>International Journal of Cosmetic Science</SO>
<YR>1991</YR>
<VL>3</VL>
<PG>51-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Osman-2008" MODIFIED="2010-12-13 12:37:50 +0000" MODIFIED_BY="Lynn Hampson" NAME="Osman 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-12-13 12:36:26 +0000" MODIFIED_BY="Lynn Hampson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Osman H, Usta IM, Rubeiz N, Abu-Rustum R, Charara I, Nassar AH</AU>
<TI>Cocoa butter lotion for prevention of striae gravidarum: a double-blind, randomised and placebo-controlled trial</TI>
<SO>BJOG: an international journal of obstetrics and gynaecology</SO>
<YR>2008</YR>
<VL>115</VL>
<NO>9</NO>
<PG>1138-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2010-12-13 12:37:50 +0000" MODIFIED_BY="Lynn Hampson" PRIMARY="NO" TYPE="OTHER">
<AU>Osman H</AU>
<TI>Cocoa butter for prevention of stretch marks</TI>
<SO>ClinicalTrials.gov (http://clinicaltrials.gov/ct2/show/NCT00114660)</SO>
<YR>(accessed 21 March 2006)</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Taavoni-2011" MODIFIED="2012-03-15 09:46:44 +0000" MODIFIED_BY="[Empty name]" NAME="Taavoni 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-03-15 09:46:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taavoni S, Soltanipour F, Haghani H, Ansarian H, Kheirkhah M</AU>
<TI>Effects of olive oil on striae gravidarum in the second trimester of pregnancy</TI>
<SO>Complementary Therapies in Clinical Practice</SO>
<YR>2011</YR>
<VL>17</VL>
<NO>3</NO>
<PG>167-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wierrani-1992" NAME="Wierrani 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;[10003]&lt;br&gt;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wierrani F, Kozak W, Schramm W, Grunberger W</AU>
<TI>Attempt of preventive treatment of striae gravidarum using preventive massage ointment administration</TI>
<SO>Wiener Klinische Wochenschrift</SO>
<YR>1992</YR>
<VL>104</VL>
<PG>42-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2012-09-19 07:05:45 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Martius-1973" NAME="Martius 1973" YEAR="">
<REFERENCE NOTES="&lt;p&gt;[10477]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martius G</AU>
<TI>Prevention of striae gravidarum</TI>
<SO>Medizinische Welt</SO>
<YR>1973</YR>
<VL>24</VL>
<PG>799-800</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendez-Velarde-2010" MODIFIED="2012-03-15 09:54:22 +0000" MODIFIED_BY="[Empty name]" NAME="Mendez Velarde 2010" YEAR="2010">
<REFERENCE MODIFIED="2012-03-15 09:54:22 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Méndez Velarde FA, Salceda Pérez MA, Moya CB, Azpeitia De La O CM, Vázquez Coronado DP, Ore Colio L</AU>
<TI>Effect of a moisturizing cream in the prevention of striae gravidarum</TI>
<TO>Efecto de una crema hidratante para prevenir las estrias del embarazo</TO>
<SO>Dermatologia Revista Mexicana</SO>
<YR>2010</YR>
<VL>54</VL>
<NO>5</NO>
<PG>273-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Msika-2002" MODIFIED="2012-09-19 07:05:45 +0100" MODIFIED_BY="[Empty name]" NAME="Msika 2002" YEAR="">
<REFERENCE MODIFIED="2012-09-19 07:05:45 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Msika P, Gavaud-Kennedy C, Pitiot M, Camel E, Arnaud-Boissel L, Guillot JP</AU>
<TI>Prevention of stretch marks: A randomized double bind clinical study versus placebo</TI>
<SO>Journal of European Academy of Dermatology and Venereology</SO>
<YR>2002</YR>
<VL>16 Suppl 1</VL>
<PG>154</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2012-06-25 21:42:02 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Msika P, Gavaud-Kennedy C, Pitiot M, Camel E, Arnaud-Boissel L, Guillot JP</AU>
<TI>Prevention of stretch marks: a randomized double blind clinical study versus placebo</TI>
<SO>http://www.mustelausa.com/professional/_images/pdfs/M9.pdf (accessed 5 October 2011)</SO>
<YR>2002</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Puder--1965" NAME="Puder  1965" YEAR="1965">
<REFERENCE NOTES="&lt;p&gt;[10583]&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Puder H</AU>
<TI>Treatment of striae gravidarum</TI>
<SO>Medizinische Welt</SO>
<YR>1965</YR>
<VL>16</VL>
<PG>650-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2012-09-19 07:06:22 +0100" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Lachmann-2011" MODIFIED="2012-09-07 10:32:00 +0100" MODIFIED_BY="[Empty name]" NAME="Lachmann 2011" YEAR="2011">
<REFERENCE MODIFIED="2012-06-25 18:36:55 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Lachmann N, Biassette M, Boy E, Chadoutaud B, Msika P</AU>
<TI>Assessment of the preventive effect of a topical treatment on striae gravidarum during pregnancy: a multicenter open study on primiparae</TI>
<SO>Journal of Investigative Dermatology</SO>
<YR>September 2011</YR>
<VL>131</VL>
<NO>Issue S2, Abstract 275</NO>
<PG>S46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-06-14 16:26:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-06-14 16:26:53 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ortega-1985" MODIFIED="2012-09-19 07:06:22 +0100" MODIFIED_BY="[Empty name]" NAME="Ortega 1985" YEAR="1985">
<REFERENCE MODIFIED="2012-09-19 07:06:22 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ortega A</AU>
<TI>Clinical and experimental study of the prevention of stretch marks in pregnancy</TI>
<TO>Estudio clínico experimental de la prevención de las estrías en el embarazo</TO>
<SO>Acta Ginecologica</SO>
<YR>1985</YR>
<VL>42</VL>
<NO>1</NO>
<PG>29-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2012-09-24 12:18:50 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2012-09-24 12:18:50 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Alster-1997" MODIFIED="2012-03-15 09:33:10 +0000" MODIFIED_BY="[Empty name]" NAME="Alster 1997" TYPE="JOURNAL_ARTICLE">
<AU>Alster TS</AU>
<TI>Laser treatment of hypertrophic scars, keloids, and striae</TI>
<SO>Dermatologic Clinics</SO>
<YR>1997</YR>
<VL>15</VL>
<NO>3</NO>
<PG>419-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Archer-2004" MODIFIED="2011-07-19 14:43:20 +0100" MODIFIED_BY="[Empty name]" NAME="Archer 2004" TYPE="BOOK_SECTION">
<AU>Archer CB</AU>
<TI>Functions of the skin</TI>
<SO>Rook's Textbook of Dermatology</SO>
<YR>2004</YR>
<VL>1</VL>
<PG>4.1-4.12</PG>
<EN>7th</EN>
<ED>Burns T, Breathnach S, Cox N, Griffiths C</ED>
<PB>Blackwell Science</PB>
<CY>Malden Massachusetts</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Atwal-2006" MODIFIED="2012-03-15 09:33:01 +0000" MODIFIED_BY="[Empty name]" NAME="Atwal 2006" TYPE="JOURNAL_ARTICLE">
<AU>Atwal GSS, Manku LK, Griffiths CEM, Polson DW</AU>
<TI>Striae gravidarum in primiparae</TI>
<SO>British Association of Dermatology</SO>
<YR>2006</YR>
<VL>55</VL>
<NO>5</NO>
<PG>965-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brinkhaus-2000" MODIFIED="2012-03-15 09:33:37 +0000" MODIFIED_BY="[Empty name]" NAME="Brinkhaus 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brinkhaus B, Lindner M, Schuppan D, Hahn EG</AU>
<TI>Chemical, pharmacological and clinical profile of the East Asian medical plant Centella asiatica</TI>
<SO>Phytomedicine</SO>
<YR>2000</YR>
<VL>7</VL>
<NO>5</NO>
<PG>427-48</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bryant-1968" MODIFIED="2012-09-19 07:08:51 +0100" MODIFIED_BY="[Empty name]" NAME="Bryant 1968" TYPE="JOURNAL_ARTICLE">
<AU>Bryant WM, Greenwell JE, Weeks PM</AU>
<TI>Alterations in collagen organization during dilatation of the cervix uteri</TI>
<SO>Surgery, Gynecology &amp; Obstetrics</SO>
<YR>1968</YR>
<VL>126</VL>
<NO>1</NO>
<PG>27-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burrows-2004" MODIFIED="2011-07-19 10:56:04 +0100" MODIFIED_BY="[Empty name]" NAME="Burrows 2004" TYPE="BOOK_SECTION">
<AU>Burrows NP, Lovell CR</AU>
<TI>Disorders of connective tissue</TI>
<SO>Rook's Textbook of Dermatology</SO>
<YR>2004</YR>
<VL>3</VL>
<PG>46.1-46.71</PG>
<EN>7th</EN>
<ED>Burns T, Breathnach S, Cox N, Griffiths C</ED>
<PB>Blackwell Science</PB>
<CY>Malden Massachusetts</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burrows-2010" MODIFIED="2011-07-19 10:50:27 +0100" MODIFIED_BY="[Empty name]" NAME="Burrows 2010" TYPE="BOOK_SECTION">
<AU>Burrows NP, Lovell CR</AU>
<TI>Disorders of connective tissue</TI>
<SO>Rook's Textbook of Dermatology</SO>
<YR>2010</YR>
<VL>3</VL>
<PG>45.1-45.70</PG>
<EN>8th</EN>
<ED>Burns T, Breathnach S, Cox N, Griffiths C</ED>
<PB>Blackwell Science</PB>
<CY>Malden Massachusetts</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chang-2004" MODIFIED="2012-03-15 09:34:03 +0000" MODIFIED_BY="[Empty name]" NAME="Chang 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chang ALS, Agredano YZ, Kimball AB</AU>
<TI>Risk factors associated with striae gravidarum</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>2004</YR>
<VL>51</VL>
<NO>6</NO>
<PG>881-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2000" NAME="Clarke 2000" TYPE="OTHER">
<AU>Clarke M, Oxman AD, editors</AU>
<TI>Cochrane Reviewers&#8217; Handbook 4.2 [updated February 2003]</TI>
<SO>In: The Cochrane Library [database on CDROM]. The Cochrane Collaboration. Oxford: Update Software; 2003, Issue 2</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cunningham-2010" MODIFIED="2011-07-19 09:42:27 +0100" MODIFIED_BY="[Empty name]" NAME="Cunningham 2010" TYPE="BOOK">
<AU>Cunningham FG, Leveno KJ, Bloom SL, Hauth JC, Rouse DJ, Spong CY</AU>
<SO>Williams Obstetrics</SO>
<YR>2010</YR>
<EN>23rd</EN>
<PB>McGraw Hill</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2009-12-08 15:53:25 +0000" MODIFIED_BY="Jill V Hampson" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elsaie-2009" MODIFIED="2012-03-15 09:42:01 +0000" MODIFIED_BY="[Empty name]" NAME="Elsaie 2009" TYPE="JOURNAL_ARTICLE">
<AU>Elsaie ML, Baumann LS, Elsaaiee LT</AU>
<TI>Striae distensae (stretch marks) and different modalities of therapy: an update</TI>
<SO>Dermatologic Surgery</SO>
<YR>2009</YR>
<VL>35</VL>
<NO>4</NO>
<PG>563-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Elson-1990" MODIFIED="2012-03-15 09:42:40 +0000" MODIFIED_BY="[Empty name]" NAME="Elson 1990" TYPE="JOURNAL_ARTICLE">
<AU>Elson ML</AU>
<TI>Treatment of striae distensae with topical tretinoin</TI>
<SO>Journal of Dermatological Surgical Oncology</SO>
<YR>1990</YR>
<VL>16</VL>
<NO>3</NO>
<PG>267-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Errickson-1994" MODIFIED="2012-03-15 09:34:40 +0000" MODIFIED_BY="[Empty name]" NAME="Errickson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Errickson CV, Matus NR</AU>
<TI>Skin disorders of pregnancy</TI>
<SO>American Family Physician</SO>
<YR>1994</YR>
<VL>49</VL>
<NO>3</NO>
<PG>605-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ghasemi-2007" MODIFIED="2012-09-19 07:10:09 +0100" MODIFIED_BY="[Empty name]" NAME="Ghasemi 2007" TYPE="JOURNAL_ARTICLE">
<AU>Ghasemi A, Gorouhi F, Rashighi-Firoozabadi M, Jafarian S, Firooz A</AU>
<TI>Striae gravidarum: associated factors</TI>
<SO>Journal of the European Academy of Dermatology and Venereology</SO>
<YR>2007</YR>
<VL>21</VL>
<NO>6</NO>
<PG>743-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harbord-2006" MODIFIED="2009-12-08 15:53:25 +0000" MODIFIED_BY="Jill V Hampson" NAME="Harbord 2006" TYPE="JOURNAL_ARTICLE">
<AU>Harbord RM, Egger M, Sterne JA</AU>
<TI>A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints</TI>
<SO>Statistics in Medicine</SO>
<YR>2006</YR>
<VL>25</VL>
<NO>20</NO>
<PG>3443-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-07-19 18:03:22 +0100" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S, editors</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Horn-2007" MODIFIED="2012-03-15 09:35:03 +0000" MODIFIED_BY="[Empty name]" NAME="Horn 2007" TYPE="BOOK_SECTION">
<AU>Horn TD, Hoskyn J</AU>
<TI>Dermatologic disorders during pregnancy</TI>
<SO>Clinical Obstetrics. The Fetus &amp; Mother</SO>
<YR>2007</YR>
<PG>947-60</PG>
<EN>3rd</EN>
<ED>Reece A, Hobbins JC</ED>
<PB>Blackwell Publishing</PB>
<CY>Malden Massachusetts</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hunter-1973" MODIFIED="2012-03-15 09:35:11 +0000" MODIFIED_BY="[Empty name]" NAME="Hunter 1973" TYPE="JOURNAL_ARTICLE">
<AU>Hunter JAA</AU>
<TI>Diseases of the skin. The basis of skin therapy</TI>
<SO>British Medical Journal</SO>
<YR>1973</YR>
<VL>4</VL>
<NO>5889</NO>
<PG>411-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kang-1996" MODIFIED="2012-09-19 07:12:47 +0100" MODIFIED_BY="[Empty name]" NAME="Kang 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kang S, Kim KJ, Griffith CEM, Wong TY, Talwar HS, Fisher GJ, et al</AU>
<TI>Topical Tretinoin (retinoic acid) improves early stretch marks</TI>
<SO>Archives of Dermatology</SO>
<YR>1996</YR>
<VL>132</VL>
<NO>5</NO>
<PG>519-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kang-1998" MODIFIED="2012-09-24 12:18:50 +0100" MODIFIED_BY="[Empty name]" NAME="Kang 1998" TYPE="JOURNAL_ARTICLE">
<AU>Kang S</AU>
<TI>Topical tretinoin therapy for management of early striae</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1998</YR>
<VL>39</VL>
<NO>2 Pt 3</NO>
<PG>s90-s92</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lawley-1999" MODIFIED="2012-03-15 09:35:56 +0000" MODIFIED_BY="[Empty name]" NAME="Lawley 1999" TYPE="BOOK_SECTION">
<AU>Lawley TJ, Yancey KB</AU>
<TI>Skin changes and diseases in pregnancy</TI>
<SO>Fitzpatrick's Dermatology in General Medicine</SO>
<YR>1999</YR>
<VL>Vol II</VL>
<PG>1963-9</PG>
<EN>5th</EN>
<ED>Freedberg IM, Eisen AZ, Wolf K, Austen KF, Goldsmith LA, Katz SI, et al</ED>
<PB>McGraw Hill</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Liu-1974" MODIFIED="2012-03-15 09:36:05 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 1974" TYPE="JOURNAL_ARTICLE">
<AU>Liu DTY</AU>
<TI>Letter: Striae gravidarum</TI>
<SO>Lancet</SO>
<YR>1974</YR>
<VL>1</VL>
<NO>7858</NO>
<PG>625</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McKenzie-1971" MODIFIED="2012-03-15 09:36:15 +0000" MODIFIED_BY="[Empty name]" NAME="McKenzie 1971" TYPE="JOURNAL_ARTICLE">
<AU>McKenzie AW</AU>
<TI>Skin disorders in pregnancy</TI>
<SO>The Practitioner</SO>
<YR>1971</YR>
<VL>206</VL>
<NO>236</NO>
<PG>773-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murphy-1992" MODIFIED="2011-07-19 15:15:59 +0100" MODIFIED_BY="[Empty name]" NAME="Murphy 1992" TYPE="JOURNAL_ARTICLE">
<AU>Murphy KW, Dunphy B, O'Herlihy C</AU>
<TI>Increased maternal age protects against striae gravidarum</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>5</NO>
<PG>297-300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Murray-2009" MODIFIED="2011-07-19 12:15:17 +0100" MODIFIED_BY="[Empty name]" NAME="Murray 2009" TYPE="BOOK_SECTION">
<AU>Murray I, Hassall J</AU>
<TI>Change and adaptation in pregnancy</TI>
<SO>Myles Textbook for Midwives</SO>
<YR>2009</YR>
<PG>189-225</PG>
<EN>15th</EN>
<ED>Fraser DM, Cooper MA</ED>
<PB>Churchill Livingstone Elsevier</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Muzaffar-1998" MODIFIED="2012-03-15 09:36:41 +0000" MODIFIED_BY="[Empty name]" NAME="Muzaffar 1998" TYPE="JOURNAL_ARTICLE">
<AU>Muzaffar F, Hussain I, Haroon TS</AU>
<TI>Physiologic skin changes during pregnancy: a study of 140 cases</TI>
<SO>International Journal of Dermatology</SO>
<YR>1998</YR>
<VL>37</VL>
<NO>6</NO>
<PG>429-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nigam-1989" MODIFIED="2012-03-15 09:36:52 +0000" MODIFIED_BY="[Empty name]" NAME="Nigam 1989" TYPE="JOURNAL_ARTICLE">
<AU>Nigam PK</AU>
<TI>Striae cutis distensae</TI>
<SO>International Journal of Dermatology</SO>
<YR>1989</YR>
<VL>28</VL>
<NO>7</NO>
<PG>426-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Osman-2007" MODIFIED="2012-03-15 09:37:41 +0000" MODIFIED_BY="[Empty name]" NAME="Osman 2007" TYPE="JOURNAL_ARTICLE">
<AU>Osman H, Rubeiz N, Tamim H, Nassar AH</AU>
<TI>Risk factors for the development of striae gravidarum</TI>
<SO>American Journal of Obstetrics and Gynecology</SO>
<YR>2007</YR>
<VL>196</VL>
<NO>1</NO>
<PG>62.e1-62.e5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Papoutsis-2007" MODIFIED="2012-03-15 09:38:19 +0000" MODIFIED_BY="[Empty name]" NAME="Papoutsis 2007" TYPE="BOOK_SECTION">
<AU>Papoutsis J, Kroumpouzos G</AU>
<TI>Dermatologic disorders of pregnancy</TI>
<SO>Obstetrics. Normal and Problem Pregnancies</SO>
<YR>2007</YR>
<PG>1178-92</PG>
<EN>5th</EN>
<ED>Gabbe SG, Niebyl JR, Simpson JL</ED>
<PB>Churchill Livingstone Elsevier</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Poidevin-1959" MODIFIED="2012-03-15 09:37:52 +0000" MODIFIED_BY="[Empty name]" NAME="Poidevin 1959" TYPE="JOURNAL_ARTICLE">
<AU>Poidevin LOS</AU>
<TI>Striae gravidarum. Their relation to adrenal cortical hyperfunction</TI>
<SO>Lancet</SO>
<YR>1959</YR>
<VL>2</VL>
<NO>7100</NO>
<PG>436-9</PG>
<IDENTIFIERS MODIFIED="2011-07-18 10:56:08 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Rangel-2001" MODIFIED="2012-03-15 09:43:45 +0000" MODIFIED_BY="[Empty name]" NAME="Rangel 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rangel O, Arias I, Garcia E, Lopez-Padilla S</AU>
<TI>Topical tretinoin 0.1% for pregnancy-related abdominal striae: An open-label, multicenter, prospective study</TI>
<SO>Advances in Therapy</SO>
<YR>2001</YR>
<VL>18</VL>
<NO>4</NO>
<PG>181-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2011" MODIFIED="2011-10-05 14:26:48 +0100" MODIFIED_BY="[Empty name]" NAME="RevMan 2011" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2011</YR>
<EN>5.1</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Riley-2011" MODIFIED="2012-03-15 09:38:57 +0000" MODIFIED_BY="[Empty name]" NAME="Riley 2011" TYPE="JOURNAL_ARTICLE">
<AU>Riley D, Gates S, Neilson J, Alfirevic Z</AU>
<TI>Statistical methods can be improved within Cochrane pregnancy and childbirth reviews</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>2011</YR>
<VL>64</VL>
<NO>6</NO>
<PG>608-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Salter-2006" MODIFIED="2011-07-19 09:54:32 +0100" MODIFIED_BY="[Empty name]" NAME="Salter 2006" TYPE="JOURNAL_ARTICLE">
<AU>Salter SA, Kimball AB</AU>
<TI>Striae gravidarum</TI>
<SO>Clinics in Dermatology</SO>
<YR>2006</YR>
<VL>24</VL>
<NO>2</NO>
<PG>97-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shuster-1979" MODIFIED="2012-03-15 09:39:36 +0000" MODIFIED_BY="[Empty name]" NAME="Shuster 1979" TYPE="JOURNAL_ARTICLE">
<AU>Shuster S</AU>
<TI>The cause of striae distensae</TI>
<SO>Acta Dermato-Venereologica. Supplementum</SO>
<YR>1979</YR>
<VL>59</VL>
<NO>85</NO>
<PG>161-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Summers-2009" MODIFIED="2012-03-15 09:45:23 +0000" MODIFIED_BY="[Empty name]" NAME="Summers 2009" TYPE="JOURNAL_ARTICLE">
<AU>Summers B, Lategan M</AU>
<TI>The effect of a topically-applied cosmetic oil formulation on striae distensae</TI>
<SO>South African Family Practice</SO>
<YR>2009</YR>
<VL>51</VL>
<NO>4</NO>
<PG>332-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Thomas-2004" MODIFIED="2012-03-15 09:39:47 +0000" MODIFIED_BY="[Empty name]" NAME="Thomas 2004" TYPE="JOURNAL_ARTICLE">
<AU>Thomas RGR, Liston WA</AU>
<TI>Clinical associations of striae gravidarum</TI>
<SO>Journal of Obstetrics and Gynaecology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>3</NO>
<PG>270-1</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Venning-1946" MODIFIED="2012-03-15 09:39:54 +0000" MODIFIED_BY="[Empty name]" NAME="Venning 1946" TYPE="JOURNAL_ARTICLE">
<AU>Venning EH</AU>
<TI>Adrenal function in pregnancy</TI>
<SO>Endocrinology</SO>
<YR>1946</YR>
<VL>39</VL>
<PG>203-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Watson-1998" MODIFIED="2012-03-15 09:40:11 +0000" MODIFIED_BY="[Empty name]" NAME="Watson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Watson REB, Parry EJ, Humphries JD, Jones CJP, Polson DP, Kielty CM, et al</AU>
<TI>Fibrillin microfibrils are reduced in skin exhibiting striae distensae</TI>
<SO>British Journal of Dermatology</SO>
<YR>1998</YR>
<VL>138</VL>
<NO>6</NO>
<PG>931-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Waugh-2010" MODIFIED="2012-09-19 07:14:40 +0100" MODIFIED_BY="[Empty name]" NAME="Waugh 2010" TYPE="BOOK">
<AU>Waugh A, Grant A</AU>
<SO>Ross and Wilson Anatomy and Physiology in Health and Illness</SO>
<YR>2010</YR>
<EN>11th</EN>
<PB>Churchill Livingstone</PB>
<CY>Edinburgh</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wong-1984" MODIFIED="2012-03-15 09:40:30 +0000" MODIFIED_BY="[Empty name]" NAME="Wong 1984" TYPE="JOURNAL_ARTICLE">
<AU>Wong RC, Ellis CN</AU>
<TI>Continuing medical education. Physiologic skin changes in pregnancy</TI>
<SO>Journal of the American Academy of Dermatology</SO>
<YR>1984</YR>
<VL>10</VL>
<NO>6</NO>
<PG>929-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wong-1989" MODIFIED="2011-07-19 10:29:35 +0100" MODIFIED_BY="[Empty name]" NAME="Wong 1989" TYPE="JOURNAL_ARTICLE">
<AU>Wong RC, Ellis CN</AU>
<TI>Physiologic skin changes in pregnancy</TI>
<SO>Seminars in Dermatology</SO>
<YR>1989</YR>
<VL>8</VL>
<NO>1</NO>
<PG>7-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zheng-1985" MODIFIED="2012-06-11 15:57:11 +0100" MODIFIED_BY="[Empty name]" NAME="Zheng 1985" TYPE="JOURNAL_ARTICLE">
<AU>Zheng P, Lavker RM, Kligman AM</AU>
<TI>Anatomy of striae</TI>
<SO>British Journal of Dermatology</SO>
<YR>1985</YR>
<VL>112</VL>
<NO>2</NO>
<PG>185-93</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2012-06-11 15:58:07 +0100" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Young-1995" MODIFIED="2009-12-08 16:00:50 +0000" MODIFIED_BY="Jill V Hampson" NAME="Young 1995" NOTES="&lt;p&gt;Young GL. A cream to prevent striae gravidarum. [revised 12 May 1993] In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM]. The Cochrane Collaboration; Issue 2, Oxford: Update Software; 1995.&lt;/p&gt;" NOTES_MODIFIED="2009-12-08 16:00:50 +0000" NOTES_MODIFIED_BY="Jill V Hampson" TYPE="OTHER">
<AU>Young GL</AU>
<TI>A cream to prevent striae gravidarum. [revised 12 May 1993]</TI>
<SO>In: Enkin MW, Keirse MJNC, Renfrew MJ, Neilson JP, Crowther C (eds.) Pregnancy and Childbirth Module. In: The Cochrane Pregnancy and Childbirth Database [database on disk and CDROM] The Cochrane Collaboration; Issue 2, Oxford: Update Software, 1995</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Young-1996" MODIFIED="2012-06-11 15:58:07 +0100" MODIFIED_BY="[Empty name]" NAME="Young 1996" TYPE="COCHRANE_REVIEW">
<AU>Young G, Jewell D</AU>
<TI>Creams for preventing stretch marks in pregnancy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1996</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2012-03-12 12:33:38 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2012-03-12 12:33:38 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000066"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2011-03-10 10:53:27 +0000" MODIFIED_BY="Lynn Hampson"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2012-09-28 10:08:28 +0100" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2012-09-28 10:08:28 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2012-09-19 06:57:23 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Buchanan--2010">
<CHAR_METHODS MODIFIED="2012-09-19 06:57:16 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B>  randomised controlled trial.</P>
<P>
<B>Duration of study:</B> not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-19 06:57:23 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting: </B>antenatal clinic in the University Hospital, of the West Indies, Mona, Kingston, Jamaica.</P>
<P>
<B>Inclusion criteria: </B>'...primigravidas and multigravidas with no stretch marks' enrolled before 16 weeks' gestation.</P>
<P>
<B>Exclusion criteria: </B>'Women who were taking steroids and women with medical illnesses that caused stretch marks...'; 'Women with a twin pregnancy or polyhydramnios...'.</P>
<P>
<B>Participants randomised:</B> 150 women were randomly assigned to the intervention (cocoa butter group) and 150 women to the comparison group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-19 06:54:02 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental:  </B>application of 473 ml of cocoa butter cream containing cocoa butter cream (25%), water, glycerin (skin conditioner), distearyldimonium chloride (skin conditioner), isopropyl palmitate (emollient), cetearyl alcohol (stabilizer), propylene glycol isostearate (emollient), PPG-15 stearyl ether (1-octadecoxypropan-2-ol) emollient, hydrolysed collagen, hydrolysed elastin, tocopheryl acetate (vitamin E), dimethicone (skin conditioner). Half a cap full of cream was applied to the 4 abdominal quadrants daily (until used up).</P>
<P>
<B>Control: </B>cream which was identical to the intervention cream with the exception of addition of the 25% cocoa butter.</P>
<P>We did not consider this a true placebo as it contains other active ingredients like vitamin E.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-22 12:46:39 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Outcomes considered in the review:</B>
</P>
<UL>
<LI>presence of stretch marks;</LI>
<LI>severity of stretch marks.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-09-19 06:54:22 +0100" MODIFIED_BY="[Empty name]">
<P>'...number of stretch marks was assessed using the 4 quadrant technique of Davey (1972) with a simplification by Fletcher (unpublished), which involved using a pictorial chart to aid the providers in using Davey's technique. Digital photographs were taken of the abdomen of some women...'.</P>
<P>1 of the study authors Horace Fletcher confirmed that the percentage of women who developed striae was erroneously included in the enrolment data and that none of the woman had striae at enrolment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-19 06:56:00 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Buman-1987">
<CHAR_METHODS MODIFIED="2012-03-22 12:35:02 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Study design: </B>randomised controlled trial.</P>
<P>
<B>Duration of study: </B>not stated (states women were monitored over 10 months).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-19 06:56:00 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting: </B>Obstetrical and Gynecological Clinic in a Hospital<B> </B>in<B> </B>Cantonal, Fribourg.</P>
<P>
<B>Inclusion criteria: </B>women at the beginning of the third month of pregnancy.<B> </B>
</P>
<P>
<B>Exclusion criteria: </B>not stated.</P>
<P>
<B>Participants randomised: </B>90 women randomised: 30 women to each group (group A - Alphastria cream n = 30; group B - cream with vitamins and excipients n = 30; group C - placebo with just excipient n = 30).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-22 12:35:52 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental: </B>'Application of 10cm (3g) Alphastria cream (contains hyaluronic acid, Vitamin A, Vitamin E, allantoine, calcium pantothenate)...' daily to the thighs, abdomen and chest. 'The cream was massaged gently into each area for a few minutes each'.</P>
<P>
<B>Control: </B>application of 1 of 2 creams : 1 containing vitamins and excipients, and 1 containing excipients only.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-22 12:46:47 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Outcomes considered in the review:</B>
</P>
<UL>
<LI>presence of stretch marks.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-28 18:23:25 +0100" MODIFIED_BY="[Empty name]">
<P>As group B contains vitamins and excipients we compared group A (Alphastria cream) with group B (vitamins and excipients) and then group A and B with group C (excipients only) [MB].</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-19 06:57:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mallol-1991">
<CHAR_METHODS MODIFIED="2012-09-19 06:57:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> randomised controlled trial.</P>
<P>
<B>Duration of study:</B> 30 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-19 06:57:55 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting: </B>antenatal clinic in Barcelona.</P>
<P>
<B>Inclusion criteria: </B>women in the first 12 weeks of pregnancy.</P>
<P>
<B>Exclusion criteria: </B>none stated.</P>
<P>
<B>Participants randomised:</B> not stated, study does not state how many were randomised to the intervention and control group. Total valid cases are reported as 41 in the active cream group and 39 in the placebo group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-06-11 15:36:44 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental: </B>application of active cream (Trofolastin) (n = 41) which '...was a marketed product...' containing Centella asiatica extract and alpha- tocopherol and collagen - elastin hydrolysates. Application of active cream (Trofolastin) (n = 41) containing Centella asiatica extract and alpha- tocopherol and collagen - elastin hydrolysates. </P>
<P>&#8216;Product applied daily from the end of the 12<SUP>th</SUP> week of pregnancy to the day of labour on abdomen, breasts, buttocks and hips&#8217;. </P>
<P>
<B>Control/Comparison intervention: </B>placebo cream containing only the excipient part of the active cream and '...identical in colour, flavour and texture'. </P>
<P>&#8216;Product applied daily from the end of the 12<SUP>th</SUP> week of pregnancy to the day of labour on abdomen, breasts, buttocks and hips&#8217;.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-22 12:46:57 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Outcomes considered in the review:</B>
</P>
<UL>
<LI>presence of stretch marks;</LI>
<LI>severity of stretch marks.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-28 18:23:39 +0100" MODIFIED_BY="[Empty name]">
<P>Striae were evaluated using '...an arbitrary score 0 = no striae, 1 = few and thin striae, 2 = many thin striae or few thick striae, and 3 = many thick striae'.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-19 06:58:38 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Osman-2008">
<CHAR_METHODS MODIFIED="2012-09-19 06:58:38 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B>  randomised controlled trial.</P>
<P>
<B>Duration of study:</B> November 2004 to July 2006 (from study protocol).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-03-22 12:40:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Setting: </B>4 medical centres in Lebanon.</P>
<P>
<B>Inclusion criteria: </B>nulliparous women with a singleton pregnancy presenting to the clinic in trimester 1, '...between November 2004 and December 2005.</P>
<P>
<B>Exclusion criteria: </B>women with a '...known hypersensitivity to cocoa butter...' or the lotion components.</P>
<P>
<B>Participants randomised: </B>105 women were randomised to the intervention group (cocoa butter lotion) and 105 to the placebo lotion group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-22 12:41:05 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental: </B>application of a thin layer of a commercially available lotion containing cocoa butter and tocopheryl acetate (vitamin E) to the abdomen, breasts and thighs once daily, from '...between 12 and 18 completed weeks of gestation...' to delivery.</P>
<P>
<B>Control: </B>placebo lotion with no active ingredients, which '...was made to look, smell, and feel the same as the study lotion...'.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-22 12:47:17 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Outcomes considered in the review:</B>
</P>
<UL>
<LI>presence of stretch marks;</LI>
<LI>severity of stretch marks.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-28 18:24:10 +0100" MODIFIED_BY="[Empty name]">
<P>Trained assessors (n = 5) completed '... the data collection tools and...' assessed '...the severity of SG based on a scale developed and previously validated by the authors (Osman et al 2007). 'The scale took ...consideration the density and width of striae to estimate the surface area of the body part affected'.</P>
<P>'...funding by the Center for Research on Population and Health at the American University of Beirut, Lebanon, with generous support from the Wellcome Trust' '...and the University Research Board (URB) at the American University of Beirut, Beirut, Lebanon'.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-19 07:00:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Taavoni-2011">
<CHAR_METHODS MODIFIED="2012-09-19 06:59:48 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> randomised controlled trial.</P>
<P>
<B>Duration of study:</B> not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-19 07:00:03 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting: </B>Department of Obstetrics and Gynaecology, Lolagar Hospital and Shahid Akbarabadi Hospital, Iran University of Medical Sciences, Tehran, Iran.</P>
<P>
<B>Inclusion criteria: </B>'<B>...</B>nulliparous women aged between 20 and 30 years old, in their 18th to 20th week of gestation with body mass indices ranging between BMI 18.5--25'. </P>
<P>
<B>Exclusion criteria: </B>'<B>...</B>included: [polyhydramnios], occurrence of dermal discuses, administration of corticosteroids, application of other ointments on the abdominal area, lack of compliance with the study protocol'.</P>
<P>
<B>Participants randomised: </B>35 women were randomised to the intervention group and 35 women to the control group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-22 12:42:48 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental: </B>application of '...olive oil topically onto...' the '... abdominal skin ...twice a day...for eight weeks, ...without massaging'.  </P>
<P>Application continued until week 28.</P>
<P>
<B>Control: </B>no treatment.<B> </B>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-22 12:47:25 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Outcomes considered in this review:</B>
</P>
<UL>
<LI>presence of stretch marks.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-28 18:24:54 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2012-09-19 07:00:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wierrani-1992">
<CHAR_METHODS MODIFIED="2012-09-19 07:00:41 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design:</B> quasi-randomised controlled trial.</P>
<P>
<B>Duration of study:</B> not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-19 07:00:49 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting: </B>antenatal clinic in Vienna.</P>
<P>
<B>Inclusion criteria: </B>pregnant women &gt; 18 and &lt; 35 years.</P>
<P>
<B>Exclusion criteria: </B>history of metabolic disorders; long term medication use for example corticosteroid use; alcohol abuse; history suggestive of a complicated pregnancy.</P>
<P>
<B>Participants randomised:</B> not stated. States that '24 participants in the Verum group and 26 in the control group could be included in the final evaluation'.<B> </B>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-03-22 12:43:45 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental: </B>application of an ointment (Verum, which contained: vitamin E, essential free fatty acids (vitamin F), panthenol, hyaluronic acid, elastin and menthol. Frequency of application not stated.</P>
<P>
<B>Control: </B>no treatment.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-22 12:47:32 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Outcomes considered in the review:</B>
</P>
<UL>
<LI>presence of stretch marks.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-28 18:24:58 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2012-06-26 14:07:27 +0100" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-03-02 16:13:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martius-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-02 16:13:57 +0000" MODIFIED_BY="[Empty name]">
<P>Not stated whether this study was randomised. Review authors believe it was not and attempts to contact the author have failed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-10-05 14:20:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mendez-Velarde-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-10-05 14:20:26 +0100" MODIFIED_BY="[Empty name]">
<P>The study does not fit the criteria for inclusion in the review. It compared the application of a topical cream on wet skin versus its application on dry skin. Nor did it have a placebo or a no treatment group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-06-26 14:07:27 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Msika-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-06-26 14:07:27 +0100" MODIFIED_BY="[Empty name]">
<P>The study is at unclear risk of bias in five of the seven domains: random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment and selective reporting. While initial attempts to contact the authors were unsuccessful, eventual contact was made with Expanscience Laboratories. However, it was not possible to get further information on the trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-03-02 16:14:00 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Puder--1965">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-03-02 16:14:00 +0000" MODIFIED_BY="[Empty name]">
<P>Not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2012-09-19 07:04:03 +0100" MODIFIED_BY="Lynn Hampson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2012-09-19 07:02:30 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lachmann-2011">
<CHAR_METHODS MODIFIED="2012-09-19 07:02:14 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design: </B>unclear.</P>
<P>
<B>Duration of study:</B> not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-06-25 18:26:42 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting: </B>not stated.</P>
<P>
<B>Inclusion criteria: </B>women between '16-19 weeks of amenorrhea...'. 'Primipare were selected according [to] factors which have been associated with the SG occurrence'.</P>
<P>
<B>Exclusion criteria: </B>not stated.</P>
<P>
<B>Participants randomised:</B> unclear.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-19 07:02:30 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental:</B> unclear.</P>
<P>
<B>Control:</B> unclear.</P>
<P>Study involved the application of a cream which 'contains patented ingredients: lupeol, natural biopeptides and arabinogalactane which counteract tissue inflammation and stimulate extracellular matrix (ECM) remodelling'.</P>
<P>'The cream was applied twice daily during 5 months'.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-06-25 18:32:28 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Outcomes considered in the review:</B>
</P>
<UL>
<LI>presence of stretch marks.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-06-25 18:33:37 +0100" MODIFIED_BY="[Empty name]">
<P>Funded by Expanscience Laboratories.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2012-09-19 07:04:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ortega-1985">
<CHAR_METHODS MODIFIED="2012-09-19 07:02:51 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Study design: </B>unclear.</P>
<P>
<B>Duration of study:</B> not stated.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-09-19 07:03:18 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Setting:</B> Obstetrics and Gynaecology Department, Mother-Infant Hospital, Palma de Mallorca.</P>
<P>
<B>Inclusion criteria:</B> women in the second trimester of pregnancy who were 'not obese (more than 10% overweight)'.</P>
<P>
<B>Exclusion criteria:</B> not stated.<BR/>
<B>Participants randomised:</B> it is unclear if the women were randomised to the different groups.</P>
<P>It states that 146 women were 'distributed into groups': Group I (n = 61) was assigned to the cream with excipients only (placebo), group II (n = 55) was assigned the cream with the active ingredients while group III (n = 30) was assigned to the control arm ['neither instructed to massage nor use a cream'].<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2012-09-19 07:04:03 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Experimental:</B> application of an 'L. anti-striae cream', containing 'fitelenos (simulating factors of neo-elastogenesis and transcutaneous penetrating factors)' ...'once or twice a day' ...'on the abdomen, legs and breasts, in a down-up direction following the skin&#8217;s traction lines' from the 'second trimester' until the puerperium. 'They were advised to undergo a massage once or twice a day each lasting from 5 to 10 minutes'. Participation in exercise is also referred to but no details are given.<BR/>
<B>Control:</B> application of a cream containing excipients only 'once or twice a day', 'on the abdomen, legs and breasts, in a down-up direction following the skin&#8217;s traction lines' from the 'second trimester' until the puerperium. 'They were advised to undergo a massage once or twice a day each lasting from 5 to 10 minutes'. Participation in exercise is also referred to but no details are given.</P>
<P>Or no treatment [no massage or cream].</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-03-22 12:47:44 +0000" MODIFIED_BY="[Empty name]">
<P>
<B>Outcomes considered in the review:</B>
</P>
<UL>
<LI>presence of stretch marks;</LI>
<LI>severity of stretch marks.</LI>
</UL>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2012-09-28 10:08:28 +0100" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2012-06-18 22:01:02 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-11 15:35:27 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buchanan--2010">
<DESCRIPTION>
<P>'The women were assigned cocoa butter cream or placebo using a table of random numbers...'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-02 16:05:17 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallol-1991">
<DESCRIPTION>
<P>Probably adequate as &#8216;randomised code numbers&#8217; were used.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-11 15:40:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Osman-2008">
<DESCRIPTION>
<P>'Randomization was conducted using a computer-generated random number table'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-12 11:52:04 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taavoni-2011">
<DESCRIPTION>
<P>'Subjects were randomised using a computer-generated randomization table to either the control or intervention group'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-26 18:46:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wierrani-1992">
<DESCRIPTION>
<P>Alternate day allocation. 'On days with uneven dates the pregnant women were included in the Verum (treatment) group'. Women enrolled on even dates were given no treatment.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-12 11:50:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Buman-1987">
<DESCRIPTION>
<P>States that a randomised 'predetermined code system' was used. Insufficient Information on which to judge risk of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2012-06-26 22:56:37 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-26 09:27:30 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Buchanan--2010">
<DESCRIPTION>
<P>Insufficient information on which to judge risk of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-22 12:38:10 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mallol-1991">
<DESCRIPTION>
<P>No details given as to how women were allocated to the 2 groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-22 12:41:33 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Osman-2008">
<DESCRIPTION>
<P>Not stated how participants were allocated to each of the 2 groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-22 12:43:02 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taavoni-2011">
<DESCRIPTION>
<P>No detail given as to how women were allocated to the 2 groups.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-26 22:56:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Wierrani-1992">
<DESCRIPTION>
<P>Allocation was performed according to day of treatment (see above). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-03-12 11:50:14 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Buman-1987">
<DESCRIPTION>
<P>Treatments were administered anonymously. Insufficient information on which to judge risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-08-01 19:33:19 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2012-06-18 22:01:02 +0100" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-07-10 14:41:08 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buchanan--2010">
<DESCRIPTION>
<P>'The women and the researchers were blinded to the allocation'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-02 16:05:20 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallol-1991">
<DESCRIPTION>
<P>Both intervention and control '...creams were identical in colour, flavour and texture' and were '...marked with a randomised code number'. Codes were not opened until the data collection was complete.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-07-10 14:23:12 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Osman-2008">
<DESCRIPTION>
<P>'...researchers, study participants and their physicians were blinded to the lotion assignment'. '...Codes for the study and placebo lotions were opened after the final assessment of the last randomised woman'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-02-12 13:12:05 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taavoni-2011">
<DESCRIPTION>
<P>No information given on blinding in the study.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2011-07-26 18:50:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wierrani-1992">
<DESCRIPTION>
<P>Insufficient information to judge risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-03-12 11:50:16 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Buman-1987">
<DESCRIPTION>
<P>While treatments were administered anonymously and the study is reported as a double blind study no detail is given on who was blinded. Insufficient detail on which to judge risk of bias. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2012-06-18 22:01:02 +0100" MODIFIED_BY="[Empty name]" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-06-11 15:30:01 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buchanan--2010">
<DESCRIPTION>
<P>'...The researchers were blinded to the allocation'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-07-26 16:39:55 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallol-1991">
<DESCRIPTION>
<P>Codes were not opened until the data collection was complete.</P>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-07-10 14:17:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Osman-2008">
<DESCRIPTION>
<P>'Assessors... were blinded as to the lotion assignment'. '...Codes for the study and placebo lotions were opened after the final assessment of the last randomised woman'.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-02-12 13:12:21 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Taavoni-2011">
<DESCRIPTION>
<P>No information given on blinding of outcome assessment.</P>
<P> </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-07-26 18:52:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wierrani-1992">
<DESCRIPTION>
<P>Insufficient information to judge risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2011-08-01 15:59:03 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Buman-1987">
<DESCRIPTION>
<P>Insufficient information on which to judge risk of bias.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2012-06-18 22:01:02 +0100" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-22 12:34:27 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buchanan--2010">
<DESCRIPTION>
<P>
<B>Development of striae</B>
</P>
<P>In the intervention arm, 30 women were excluded from analysis (lost to follow up n = 28, discontinued intervention due to rash n =2). The 2 women who discontinued treatment were returned to group denominator (n = 122). 18.7% incomplete outcome data. </P>
<P>In the control arm 28 women were excluded from analysis (lost to follow up n = 27, discontinued intervention due to skin rash n = 1). The 1 woman who discontinued due to skin rash (n = 1) was restored to the group denominator (n = 123). 18% incomplete outcome data. </P>
<P>
<B>Severity of striae</B>
</P>
<P>Intervention group: data available for 101 of the 120 women. Missing data = 15.8%.</P>
<P>Control group: data available for 105 of the 122 women. Missing data = 13.9%.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-22 12:38:29 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallol-1991">
<DESCRIPTION>
<P>States &#8216;The assay was carried out on 100 pregnant women&#8217; but does not state explicitly how many women were randomised. Total &#8216;valid&#8217; cases are noted as 41 for intervention (active cream) and 39 for placebo. Assuming 100 women randomised, then 20 women were excluded from the analysis overall, due to abortion (n = 1) and &#8216;several address changes&#8217; (n = 19). 20% incomplete outcome data. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-22 12:42:10 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Osman-2008">
<DESCRIPTION>
<P>In the intervention arm (n = 105), 14 women were excluded from analysis (remaining n = 91) due to abortion n = 3, withdrew n = 2, lost to follow up n = 9. We restored n = 3 (abortion) to the group denominator (n = 94). Equates to 10.5% incomplete outcome data in the intervention group. </P>
<P>In the control arm (n = 105), 21 women were excluded from analysis (remaining n = 84) due to abortion n = 5, withdrew n = 6, lost to follow up n = 9, allergic reaction n = 1). We restored n = 6 (abortion, and allergic reaction) to the group denominator (n = 90). Equates to 14.3% incomplete outcome data in the control arm.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-02-12 13:13:26 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taavoni-2011">
<DESCRIPTION>
<P>None (percentages in Table 2, p. 168 suggest no losses to follow up).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-02 16:13:45 +0000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wierrani-1992">
<DESCRIPTION>
<P>Number of women randomised not given. States that '24 participants in the Verum group and 26 in the control group could be included in the final evaluation'. </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-03-22 12:36:23 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Buman-1987">
<DESCRIPTION>
<P>In the control arm (group C) (n = 30), 3 women were excluded from the analysis (withdrawals due to intolerance, allergy, and miscarriage). We restored these 3 women to the group denominator (n = 30). </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2012-06-18 22:01:02 +0100" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 17:58:54 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Buchanan--2010">
<DESCRIPTION>
<P>The protocol was not available and following clarification from the authors all the outcomes stated in the methods section were reported adequately in the results.   </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-26 16:44:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mallol-1991">
<DESCRIPTION>
<P>The protocol was not available but all the outcomes stated in the methods section were reported in the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-07-26 18:06:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Osman-2008">
<DESCRIPTION>
<P>Study protocol is available and all outcomes have been reported as planned. However a secondary outcome (severity of striae) is reported in the study which is not identified as such in the protocol. Study protocol reports that women will be asked to give their assessment of the presence or absence of striae and their severity'. Trained assessors assessed the severity of striae in the study.<B> </B>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-02-12 13:13:48 +0000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taavoni-2011">
<DESCRIPTION>
<P>The protocol was not available but the outcome stated in the methods section was reported adequately in the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 18:12:57 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Wierrani-1992">
<DESCRIPTION>
<P>The protocol was not available but all the outcomes stated in the methods section were reported adequately in the results.  </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-08-01 18:13:43 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Buman-1987">
<DESCRIPTION>
<P>The protocol was not available but all the outcomes stated in the methods section were reported adequately in the results.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2012-09-28 10:08:28 +0100" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-28 18:23:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Buchanan--2010">
<DESCRIPTION>
<P>
<B>Intervention integrity</B>
</P>
<P>Authors state '...that it was not possible to verify that the patients were using the cream as instructed or whether<B> </B>they were sharing the cream or using other creams'.</P>
<P>
<B>Funding source</B>
</P>
<P>No funding source identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-28 18:23:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mallol-1991">
<DESCRIPTION>
<P>Number of women randomised into each group is not given. States &#8216;The assay was carried out on 100 pregnant women&#8217; but does not state explicitly how many women were randomised&#8217;.</P>
<P>
<B>Funding source</B>
</P>
<P>No funding source identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-19 06:59:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Osman-2008">
<DESCRIPTION>
<P>
<B>Intervention integrity</B>
</P>
<P>Authors state that 'Reports of compliance varied greatly for each patient and assessors reported that women may have been telling them what they wanted to hear when they asked about compliance'.</P>
<P>
<B>Funding source</B>
</P>
<P>Both study and placebo lotions were provided by ET Browne Drug Company, Inc.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-28 18:24:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Taavoni-2011">
<DESCRIPTION>
<P>None identified.</P>
<P>
<B>Funding source</B>
</P>
<P>Authors declared no funding source.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-06-28 18:25:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Wierrani-1992">
<DESCRIPTION>
<P>Number of women randomised into each group is not given. States that '24 participants in the Verum group and 26 in the control group could be included in the final evaluation'.</P>
<P>
<B>Funding source</B>
</P>
<P>No funding source identified.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-09-28 10:08:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Buman-1987">
<DESCRIPTION>
<P>None identified.  </P>
<P>
<B>Funding source</B>
</P>
<P>No funding source identified.                                                          </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2012-10-05 10:32:28 +0100" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2012-10-05 10:32:19 +0100" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Topical preparations with active ingredients compared with placebo or no treatment</NAME>
<DICH_OUTCOME CHI2="11.587723480223353" CI_END="1.0316747489149405" CI_START="0.5280972960707655" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7381223782859221" ESTIMABLE="YES" EVENTS_1="127" EVENTS_2="141" I2="65.48070890001165" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.013542800958358841" LOG_CI_START="-0.27728605615201324" LOG_EFFECT_SIZE="-0.13187162759682725" METHOD="MH" MODIFIED="2012-06-25 14:50:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.020695487894867526" P_Q="1.0" P_Z="0.07549788828748903" Q="0.0" RANDOM="YES" SCALE="26.31" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.08662913955617108" TOTALS="YES" TOTAL_1="254" TOTAL_2="220" WEIGHT="100.00000000000001" Z="1.777427750743252">
<NAME>Presence of stretch marks</NAME>
<GROUP_LABEL_1>Active preparations</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours active prep.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4648796310232826" CI_START="0.38399059423542475" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.16580194023274877" LOG_CI_START="-0.41567941344934867" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2012-02-16 10:45:01 +0000" MODIFIED_BY="[Empty name]" ORDER="456" O_E="0.0" SE="0.34156502553198664" STUDY_ID="STD-de-Buman-1987" TOTAL_1="60" TOTAL_2="30" VAR="0.1166666666666667" WEIGHT="14.355614173954216"/>
<DICH_DATA CI_END="1.0047787195854547" CI_START="0.36467146508502574" EFFECT_SIZE="0.6053215077605322" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="22" LOG_CI_END="0.0020704284786327632" LOG_CI_START="-0.43809821815304173" LOG_EFFECT_SIZE="-0.21801389483720449" MODIFIED="2012-02-16 10:44:59 +0000" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="0.25855724190138674" STUDY_ID="STD-Mallol-1991" TOTAL_1="41" TOTAL_2="39" VAR="0.06685184733965222" WEIGHT="19.014968670347006"/>
<DICH_DATA CI_END="1.1722052751664942" CI_START="0.8726326726105734" EFFECT_SIZE="1.0113874737788433" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="71" LOG_CI_END="0.06900367146510576" LOG_CI_START="-0.059168530440603787" LOG_EFFECT_SIZE="0.0049175705122509895" MODIFIED="2012-02-16 10:44:50 +0000" MODIFIED_BY="[Empty name]" ORDER="458" O_E="0.0" SE="0.07528898586204572" STUDY_ID="STD-Osman-2008" TOTAL_1="94" TOTAL_2="90" VAR="0.0056684313921353206" WEIGHT="31.619858760449542"/>
<DICH_DATA CI_END="1.1312809033387212" CI_START="0.4675457866156016" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="22" LOG_CI_END="0.05357045605075255" LOG_CI_START="-0.3301758523833154" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2012-02-20 11:46:37 +0000" MODIFIED_BY="[Empty name]" ORDER="16" O_E="0.0" SE="0.22541448114903426" STUDY_ID="STD-Taavoni-2011" TOTAL_1="35" TOTAL_2="35" VAR="0.05081168831168832" WEIGHT="21.234128188778882"/>
<DICH_DATA CI_END="0.9483329054577518" CI_START="0.2368751526423952" EFFECT_SIZE="0.4739583333333333" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="16" LOG_CI_END="-0.023039179936599777" LOG_CI_START="-0.6254804928283123" LOG_EFFECT_SIZE="-0.32425983638245603" MODIFIED="2012-06-25 14:50:48 +0100" MODIFIED_BY="[Empty name]" ORDER="454" O_E="0.0" SE="0.35387700932518595" STUDY_ID="STD-Wierrani-1992" TOTAL_1="24" TOTAL_2="26" VAR="0.12522893772893773" WEIGHT="13.775430206470357"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="7.707562001941202" CI_END="0.44215471289717384" CI_START="-1.0584718432431957" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.30815856517301093" ESTIMABLE="YES" I2="87.02572876159617" I2_Q="0.0" ID="CMP-001.02" MODIFIED="2011-07-30 15:50:54 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.005499009797786281" P_Q="1.0" P_Z="0.4208369916758139" Q="0.0" RANDOM="YES" SCALE="21.37" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.25576095044670416" TOTALS="YES" TOTAL_1="132" TOTAL_2="123" UNITS="" WEIGHT="100.0" Z="0.8049700130858458">
<NAME>Severity of stretch marks</NAME>
<GROUP_LABEL_1>Active preparations</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo or no treatment</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours active prep.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.25861735665868757" CI_START="-1.1640932628657992" EFFECT_SIZE="-0.7113553097622434" ESTIMABLE="YES" MEAN_1="1.42" MEAN_2="2.13" MODIFIED="2011-07-29 15:24:56 +0100" MODIFIED_BY="[Empty name]" ORDER="33" SD_1="0.5" SD_2="1.32" SE="0.23099299613395705" STUDY_ID="STD-Mallol-1991" TOTAL_1="41" TOTAL_2="39" WEIGHT="47.40932621952261"/>
<CONT_DATA CI_END="0.35192831894308224" CI_START="-0.24129960049960247" EFFECT_SIZE="0.05531435922173988" ESTIMABLE="YES" MEAN_1="2.2" MEAN_2="2.1" MODIFIED="2011-07-29 15:31:51 +0100" MODIFIED_BY="[Empty name]" ORDER="34" SD_1="1.8" SD_2="1.8" SE="0.15133643376153613" STUDY_ID="STD-Osman-2008" TOTAL_1="91" TOTAL_2="84" WEIGHT="52.59067378047739"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2012-10-05 10:32:28 +0100" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Topical preparations with active ingredients compared with other topical preparations with active ingredient</NAME>
<DICH_OUTCOME CHI2="3.884722324689484" CI_END="1.5987813599798315" CI_START="0.16433041961034514" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5125703968731359" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="80" I2="74.25813439368713" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.2037890762248621" LOG_CI_START="-0.7842820357976086" LOG_EFFECT_SIZE="-0.2902464797863732" METHOD="MH" MODIFIED="2012-02-16 10:36:52 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.04872737533291194" P_Q="1.0" P_Z="0.24953435130420154" Q="0.0" RANDOM="YES" SCALE="51.22" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5291988462865929" TOTALS="YES" TOTAL_1="152" TOTAL_2="153" WEIGHT="100.0" Z="1.1514811840949504">
<NAME>Presence of stretch marks</NAME>
<GROUP_LABEL_1>Active preparations</GROUP_LABEL_1>
<GROUP_LABEL_2>Other active preparations</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours active prep.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other active prep</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0329480146932528" CI_START="0.6205571594415733" EFFECT_SIZE="0.8006268081002893" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="68" LOG_CI_END="0.014078465275702973" LOG_CI_START="-0.20721820951293918" LOG_EFFECT_SIZE="-0.0965698721186181" MODIFIED="2011-07-29 15:02:37 +0100" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.1299907622070556" STUDY_ID="STD-Buchanan--2010" TOTAL_1="122" TOTAL_2="123" VAR="0.016897598259171275" WEIGHT="61.685382105847715"/>
<DICH_DATA CI_END="0.7971088533451651" CI_START="0.07840836259403103" EFFECT_SIZE="0.25" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.09848236721230207" LOG_CI_START="-1.1056376154436227" LOG_EFFECT_SIZE="-0.6020599913279624" MODIFIED="2011-07-29 15:04:47 +0100" MODIFIED_BY="[Empty name]" ORDER="459" O_E="0.0" SE="0.5916079783099616" STUDY_ID="STD-de-Buman-1987" TOTAL_1="30" TOTAL_2="30" VAR="0.35" WEIGHT="38.31461789415229"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.1277989897877443" CI_START="-0.5277989897877442" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2012-03-12 11:54:21 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.23176181934412954" Q="0.0" RANDOM="YES" SCALE="1.4" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="101" TOTAL_2="105" UNITS="" WEIGHT="100.0" Z="1.1958328400030553">
<NAME>Severity of stretch marks</NAME>
<GROUP_LABEL_1>Active preparations</GROUP_LABEL_1>
<GROUP_LABEL_2>Other active preparations</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours active prep.</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours other active prep</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.1277989897877443" CI_START="-0.5277989897877442" EFFECT_SIZE="-0.19999999999999996" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="1.2" MODIFIED="2011-07-29 15:37:09 +0100" MODIFIED_BY="[Empty name]" ORDER="35" SD_1="1.2" SD_2="1.2" SE="0.16724745575601432" STUDY_ID="STD-Buchanan--2010" TOTAL_1="101" TOTAL_2="105" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2012-09-28 10:08:29 +0100" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2012-09-28 10:08:29 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2012-09-28 10:08:29 +0100" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2012-03-12 12:05:00 +0000" MODIFIED_BY="Jill V Hampson">
<APPENDIX ID="APP-01" MODIFIED="2012-03-12 12:05:00 +0000" MODIFIED_BY="Jill V Hampson" NO="1">
<TITLE MODIFIED="2009-12-08 15:49:02 +0000" MODIFIED_BY="Jill V Hampson">Methods used to assess trials included in previous versions of this review</TITLE>
<APPENDIX_BODY MODIFIED="2012-03-12 12:05:00 +0000" MODIFIED_BY="Jill V Hampson">
<P>The following methods were used to assess <LINK REF="STD-Mallol-1991" TYPE="STUDY">Mallol 1991</LINK>, <LINK REF="STD-Wierrani-1992" TYPE="STUDY">Wierrani 1992</LINK> in previous versions of this review (<LINK REF="REF-Young-1996" TYPE="REFERENCE">Young 1996</LINK>).</P>
<P>We evaluated trials under consideration for methodological quality and appropriateness for inclusion, without consideration of their results. We processed trial data as described in <LINK REF="REF-Clarke-2000" TYPE="REFERENCE">Clarke 2000</LINK>.</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>